US20170274011A1 - Injectable slurries and methods of manufacturing and using the same - Google Patents

Injectable slurries and methods of manufacturing and using the same Download PDF

Info

Publication number
US20170274011A1
US20170274011A1 US15/505,042 US201515505042A US2017274011A1 US 20170274011 A1 US20170274011 A1 US 20170274011A1 US 201515505042 A US201515505042 A US 201515505042A US 2017274011 A1 US2017274011 A1 US 2017274011A1
Authority
US
United States
Prior art keywords
slurry
proximate
tissue
group
ice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/505,042
Other languages
English (en)
Inventor
Lilit Garibyan
Richard Rox Anderson
William A. Farinelli
Emilia Javorsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to US15/505,042 priority Critical patent/US20170274011A1/en
Publication of US20170274011A1 publication Critical patent/US20170274011A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00434—Neural system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
    • A61B2018/0293—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument interstitially inserted into the body, e.g. needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
    • A61F2007/0059—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit
    • A61F2007/0063—Heating or cooling appliances for medical or therapeutic treatment of the human body with an open fluid circuit for cooling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • One aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible surfactant.
  • the plurality of sterile ice particles can have a largest cross-sectional dimension less than a value selected from the group consisting of: about 1.25 mm, about 1 mm, about 0.9 mm, about 0.8 mm, about 0.7 mm, about 0.6 mm, about 0.5 mm, about 0.4 mm, about 0.3 mm, about 0.2 mm, and about 0.1 mm.
  • the biocompatible surfactant can be one or more selected from the group consisting of: a solvent, a detergent, a wetting agent, an emulsifier, a foaming agent, and a dispersant.
  • the biocompatible surfactant can be one or more selected from the group consisting of: anionic, cationic, amphoteric, and nonionic.
  • the biocompatible surfactant can be glycerol.
  • the biocompatible surfactant can be urea.
  • the plurality of ice particles can constitute between about 0.1% and about 75% of the slurry by weight.
  • the plurality of ice particles can constitute a percentage by weight selected from the group consisting of: between about 0.1% and 1%, between about 1% and 10%, between about 10% and about 20%, between about 20% and about 30%, between about 30% and about 40%, between about 40% and about 50%, between about 50% and about 60%, between about 60% and about 70%, and greater than about 50%.
  • the plurality of ice particles can constitute between about 0.1% and about 50% of the slurry by weight.
  • the slurry can further include a therapeutic compound.
  • the therapeutic compound can be selected from the group consisting of: an anesthetic and an analgesic.
  • the therapeutic compound can be a water-soluble anesthetic.
  • the therapeutic compound can be selected from the group consisting of: prilocaine, bupivacaine, prilocaine, tetracaine, procaine, mepivicaine, etidocaine, lidocaine, QX-314, and a nonsteroidal anti-inflammatory drugs (NSAID).
  • NSAID nonsteroidal anti-inflammatory drugs
  • the therapeutic compound can be a vasoconstrictor.
  • the vasoconstrictor can be selected from the group consisting of: epinephrine, norepinephrine, a selective adrenergic agonist, a nonselective adrenergic agonist, and a corticosteroid.
  • the slurry can further include one or more selected from the group consisting of: microbubbles, nanobubbles, and biodegradable solids.
  • the slurry can further include a toxin.
  • the toxin can be ethanol.
  • the slurry can be hypertonic.
  • the slurry can be hypotonic.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and about ⁇ 50° C., and between about ⁇
  • the slurry can have a mean temperature of about +5° C. or lower.
  • Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; a biocompatible surfactant; and a foam comprising a plurality of gas bubbles.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and
  • Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a biocompatible excipient.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and
  • Another aspect of the invention provides a slurry including: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and a lipolytic agent.
  • the lipolytic agent can be a detergent.
  • the detergent can be deoxycholate.
  • the lipolytic agent can be an alcohol.
  • the lipolytic agent can be an organic solvent.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and about ⁇ 50° C., and between about ⁇
  • Another aspect of the invention a method of treating a subject.
  • the method includes: injecting a slurry as described herein into a treatment region of the subject.
  • the treatment region can be selected from the group consisting of: proximate to a nerve, proximate to subcutaneous adipose tissue, proximate to breast tissue, proximate to visceral fat, fatty tissue proximate to the pharynx, fatty tissue proximate to the palate, fatty tissue proximate to the tongue, proximate to a spinal cord lipoma, proximate to a lipomyelomeningocele, proximate to visceral fat, proximate to lipomastia, proximate to a tumor, proximate to cardiac tissue, proximate to pericardial fat, and proximate to epicardial fat.
  • the treatment region can include one or more tissues selected from the group consisting of: connective, epithelial, neural, joint, cardiac, adipose, hepatic, renal, vascular, cutaneous, and muscle.
  • the method can further include measuring a temperature of the slurry prior to injection.
  • the slurry can be injected via gravity flow.
  • the slurry can be injected via pressure injection.
  • the slurry can be injected through one or more selected from the group consisting of: a syringe, a cannula, a catheter, and tubing.
  • the method can further include pre-cooling the treatment region prior to the injecting step.
  • the method can further include applying energy adjacent to the target tissue.
  • the method can further include applying suction to the treatment region to remove melted slurry.
  • the injecting step can include injecting a sufficient volume of the slurry to cause tumescent swelling of the treatment region.
  • the injecting step can be repeated a plurality of times.
  • the method can further include calculating a desired amount of slurry to be injected based on a desired amount of disruption to the treatment region.
  • the slurry can cool the treatment region adjacent to an injection site at a rate greater in magnitude than about ⁇ 2° C. per minute.
  • the method can thicken septa.
  • the septa can be in adipose tissue and/or dermis.
  • the method can further include mixing the slurry with relatively warmer liquid prior to the injecting step.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and about ⁇ 50° C., and between about ⁇
  • the slurry can be hypotonic relative to the treatment region.
  • the slurry can be isotonic relative to the treatment region.
  • the slurry can be hypertonic relative to the treatment region.
  • Another aspect of the invention provides a method of treating a subject.
  • the method includes: injecting the slurry as described herein having a temperature and cooling capacity sufficient to non-selectively disrupt tissue into a treatment region of the subject.
  • the treatment region can be selected from the group consisting of: a prostate, a kidney, a heart, and a fibroadenoma.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and about ⁇ 50° C., and between about ⁇
  • the slurry can be hypotonic relative to the treatment region.
  • the slurry can be isotonic relative to the treatment region.
  • the slurry can be hypertonic relative to the treatment region.
  • Another aspect of the invention provides a method of treating a subject.
  • the method includes injecting a slurry into a treatment region of the subject selected from the group consisting of: proximate to a nerve, proximate to subcutaneous adipose tissue, proximate to breast tissue, proximate to visceral fat, fatty tissue proximate to the pharynx, fatty tissue proximate to the palate, fatty tissue proximate to the tongue, proximate to a spinal cord lipoma, proximate to a lipomyelomeningocele, proximate to visceral fat, proximate to lipomastia, proximate to a tumor, proximate to cardiac tissue, proximate to pericardial fat, and proximate to epicardial fat.
  • the slurry can include an ionic component.
  • the slurry can have a temperature and cooling capacity sufficient to non-selectively disrupt tissue into a treatment region of the subject.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15°
  • Another aspect of the invention provides a method of preparing a slurry.
  • the method includes: freezing a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm in one or more micromolds; and mixing the plurality of sterile ice particles with one or more biocompatible liquids.
  • the plurality of sterile ice particles can have a substantially uniform shape.
  • the one or more micromolds can be fabricated from one or more materials selected from the group consisting of: polymers, plastics, elastomers, silicons, silicones, and metals.
  • the method can further include applying mechanical strain, stress waves, shock waves, or centripetal force to remove the plurality of sterile ice particles from the one or more micromolds.
  • the slurry can have a mean temperature selected from the group consisting of: about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and about ⁇ 50° C., and between about ⁇
  • Another aspect of the invention provides a slurry comprising: a plurality of sterile ice particles having a largest cross-sectional dimension less than about 1.5 mm; and an ionic component selected from the group consisting of: hydrogen ions, lactate, phosphate, zinc ions, sulfur ions, nitrate, ammonium, hydroxide, iron ions, barium ions.
  • FIG. 1 depicts a method of preparing a slurry according to an embodiment of the invention.
  • FIG. 2 depicts a method of preparing a slurry according to an embodiment of the invention.
  • FIG. 3 depicts an experimental prototype for generating slurries according to an embodiment of the invention.
  • FIG. 4 depicts an example of ice produced by introducing droplets generated by an ultrasonic humidifier into a dry ice environment according to an embodiment of the invention.
  • FIG. 5 depicts ice balls harvested using liquid nitrogen according to an embodiment of the invention.
  • FIG. 6 depicts a general method of treatment using injectable slurries according to an embodiment of the invention.
  • FIG. 7 depicts an ice slurry with a high concentration of small ice particles according to an embodiment of the invention.
  • FIGS. 8A-8C depict the results of injection of an ice slurry into human abdominoplasty adipose tissue according to an embodiment of the invention.
  • FIGS. 9A and 9B depict the detection of injected slurry with ultrasound in ex vivo human skin according to an embodiment of the invention.
  • FIG. 9A is an ultrasound image of human skin prior to slurry injection.
  • FIG. 9B is an ultrasound image of human skin after slurry injection.
  • FIG. 10 depicts a chart of the temperature of an ex vivo human abdominoplasty specimen being heated from below after injection of a cold slurry according to an embodiment of the invention.
  • FIGS. 11A and 11B depict gross photographs of pig skin 4 weeks after injections of a melted, room temperature slurry ( FIG. 11A ) and cold slurry ( FIG. 11B ) according to embodiments of the invention.
  • FIGS. 12A and 12B depict ultrasound images of pig skin at a treatment site prior to cold slurry injection ( FIG. 12A ) and 4 weeks after cold slurry injection ( FIG. 12B ) according to an embodiment of the invention.
  • FIGS. 13A and 13B depict gross photographs of pig skin at another treatment site 4 weeks after injections of cold slurry according to an embodiment of the invention demonstrating a marked depression in skin caused by loss of subcutaneous fat at the site of the injection.
  • FIGS. 14A and 14B depict ultrasound images of pig skin at another treatment site prior to cold slurry injection ( FIG. 14A ) and 4 weeks after cold slurry injection ( FIG. 14B ) according to an embodiment of the invention.
  • FIG. 15 depicts the creation of a slurry using a benchtop analytical mill according to an embodiment of the invention.
  • FIG. 16 depicts an injection site in the area of the left inguinal fat pad in adult Sprague-Dawley rats.
  • FIGS. 17A, 17B, and 17C depicts the result of injection of room temperature hetastarch solutions, injection of cold hetastarch slurry, and no injection in a control site, respectively, in adult Sprague-Dawley rats.
  • FIGS. 18A and 18B depict the result of injections of 5% TWEEN® 20 (polysorbate 20) in lactated Ringer's solution plus 5% dextrose at room temperature (+16° C.) and cold slurry ( ⁇ 0.6° C.), respectively, in adult Sprague-Dawley rats.
  • FIG. 18C depicts the control (not injected) side.
  • FIGS. 18D-18G depict tissue surrounding the injection site demonstrating no effect on muscle or surrounding tissue.
  • FIGS. 19A and 19B depict the result of injections of 5% polyethylene glycol (PEG) in lactated Ringer's solution plus 5% dextrose at room temperature (+8° C.) and cold slurry ( ⁇ 0.8° C.), respectively, in adult Sprague-Dawley rats.
  • FIG. 19C depicts the control (not injected) side.
  • FIGS. 19D-19G depict tissue surrounding the injection site demonstrating no effect on muscle or surrounding tissue.
  • FIG. 20A depicts injection sites on a swine before injection and FIG. 20B depicts injection sites 14 days after injection.
  • FIG. 21 depicts a graph of cooling at three locations during slurry injection into a swine.
  • FIGS. 22A-22D are photographs of injection site 11, which received an injection of normal slurry with 10% glycerol at ⁇ 4.1° C.
  • FIGS. 23A and 23B depict a foamy slurry.
  • FIG. 24 depicts the use of a foamy slurry as an insulator for further slurry injection(s).
  • FIG. 25A depicts an injection site for porcine parapharyngeal and neck fat pads.
  • FIG. 25B depicts the injection depth.
  • FIGS. 25C and 25D depict the localization of the slurry (containing ink) within the parapharyngeal and neck fat pads.
  • FIGS. 26A-26K are photographs depicting the result of various slurry compositions into swine.
  • FIGS. 27A-27C depict various structures for removal of melted slurry from an injection site according to an embodiment of the invention.
  • FIG. 28 depicts a tray for molding micro ice particles and a micro ice particle that can be formed from such a tray according to an embodiment of the invention.
  • FIGS. 29A-29D depict histology of the perigonadal visceral fat of obese mice.
  • FIG. 30 is a graph of average weight loss of obese mice treated with intraperitoneal injection of cold slurry compared to their untreated cohort.
  • FIGS. 31A and 31B provides images of gross biopsies of swine taken at time of sacrifice three months post-procedure and showing a visible dermal thickening in the treated region.
  • FIGS. 32A and 32B provide images of histology of swine taken at time of sacrifice three months post-procedure and stained with hematoxylin and eosin (H&E).
  • FIG. 33A depicts a quantitative model to illustrate the behavior of injected slurries according to an embodiment of the invention.
  • FIG. 33B depicts three stages of heat exchange following infusion of a slurry into a tissue.
  • FIGS. 34A and 34B provide images of immunohistochemical (IHC) staining for type I collagen taken at time of sacrifice three months post-procedure.
  • IHC immunohistochemical
  • FIGS. 35A and 35B provide images of immunohistochemical (IHC) staining for type III collagen taken at time of sacrifice three months post-procedure.
  • IHC immunohistochemical
  • FIGS. 36A and 36B are magnetic resonance (MR) images depicting the cross-sections of a control mouse trachea and adjacent tissue at a baseline and four week follow-up, respectively.
  • MR magnetic resonance
  • FIGS. 37A and 37B are magnetic resonance (MR) images depicting the cross-sections of a treated mouse trachea and adjacent tissue at a baseline and four week follow-up, respectively.
  • MR magnetic resonance
  • the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
  • Ranges provided herein are understood to be shorthand for all of the values within the range.
  • a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
  • slurry refers to a plurality of ice particles in an aqueous solution.
  • a composition including a cold slurry e.g., ice slurry
  • tissue e.g., directly into the tissue rather than through a natural conduit of the body such as arteries, veins, or gut.
  • a cold slurry e.g., ice slurry
  • tissue e.g., directly into the tissue rather than through a natural conduit of the body such as arteries, veins, or gut.
  • a volume of ice slurry is directly introduced into a volume of soft tissue, there is rapid heat exchange between the tissue and the slurry.
  • a pool of slurry is produced that contacts a target volume of local tissue.
  • a slurry is infused more slowly and with larger volume, the slurry penetrates and flows through spaces in the tissue, producing widespread channels filled with slurry in a process similar to the administration of tumescent anesthesia.
  • Infusion enables sustained flow of slurry through tissue, especially tissue nearby the site of introduction. This tissue can be profoundly cooled to the temperature
  • Gradual warming occurs by a combination of heat diffusion from surrounding warm tissue and by convective heating from blood flow. Blood flow can be reduced in the local tissue by pressure or by drugs as discussed in greater detail herein.
  • the desired level of pain relief may depend on temperature, rate of cooling, duration of cooling and the number of cooling cycles.
  • Embodiments of the invention provide injectable slurries that can be used for selective or non-selective cryotherapy and/or cryolysis. Without being bound by theory, it is believed that such slurries can target and disrupt desired tissue through the extraction of heat from adjacent tissue during melting of the ice component of the slurry.
  • the osmolality or osmolarity of the slurry can be adjusted to synergistically induce selective damage through hypertonic or hypotonic injury.
  • the slurries can be isotonic slurries having an osmolarity of about 308 mOsm/L, hypotonic slurries having an osmolarity less than about 308 mOsm/L, or hypertonic slurries having an osmolarity greater than about 308 mOsm/L.
  • additives such as freezing point depressants can be added to the slurries.
  • the additives can constitute less than about 20% w/w of the slurry, between about 20% and about 40% w/w of the slurry, and the like.
  • the injectable slurry includes a plurality of sterile ice particles and one or more freezing point depressants.
  • the freezing point depressants can also alter the viscosity of the slurry, prevent agglomeration of the ice particles, increase thermal conductivity of fluid phase, and otherwise improve the performance of the slurry.
  • the degree of freezing point depression can be calculated either using the idealized formula
  • ⁇ T F is the freezing point depression (as defined by T F(pure solvent) ⁇ T F(solution) )
  • K F is the cryoscopic constant
  • b is molality
  • i is the van 't Hoff factor representing the number of ion particles per individual molecule of solute (e.g., 2 for NaCl, 3 for BaCl 2 ) or in the formulas proposed in X.
  • Ge & X. Wang, “Estimation of Freezing Point Depression, Boiling Point Elevation and Vaporization enthalpies of electrolyte solutions,” 48 Ind. Eng. Chem. Res. 2229-35 (2009) and X. Ge & X.
  • the size of the ice particles can be controlled. Without being bound by theory, it is believed that a slurry will be injectable if all or most (e.g., greater than about 50% by quantity, greater than about 75% by quantity, greater than about 80% by quantity, greater than about 90% by quantity, greater than about 95% by quantity, greater than about 99% by quantity, and the like) of the ice particles have a largest cross-sectional dimension (i.e., the largest distance between any two points on the surface of the ice particle) no greater than half of the internal diameter of the vessels (e.g., needles, cannulae, catheters, tubing, and the like) to be used.
  • the vessels e.g., needles, cannulae, catheters, tubing, and the like
  • the ice particles will preferably have a largest cross-sectional dimension less than or equal to about 1.5 mm. In some embodiments, the ice particles have a mean largest cross-sectional dimension of 1 mm or less.
  • this controlled size can be achieved by controlled generation or processing of the ice particles and/or by filtering, screening, or sorting of the ice particles.
  • Controlled storage, transport, and/or handling of the ice particles and/or slurries can also promote predictable, flowable slurries by preventing thawing and refreezing of the ice particles, which may change the size of the ice particles and/or produce sharp and/or jagged surfaces.
  • exemplary suitable ice particle sizes for various internal catheter diameters and internal needle diameters are provided in Table 1 and Table 2, respectively, below.
  • One or more freezing point depressants can be added to form sub ⁇ 0° C. slurries that remain injectable. Freezing point depressants can also reduce the temperature of the slurries to temperatures below 0° C.
  • Suitable freezing point depressants include biocompatible compounds such salts (e.g., sodium chloride), ions, Lactated Ringer's solution, sugars (e.g., glucose, sorbitol, mannitol, hetastarch, sucrose, or a combination thereof), biocompatible surfactants such as glycerol (also known as glycerin or glycerine), other polyols, other sugar alcohols, and/or urea, and the like.
  • biocompatible compounds such salts (e.g., sodium chloride), ions, Lactated Ringer's solution, sugars (e.g., glucose, sorbitol, mannitol, hetastarch, sucrose, or a combination thereof), biocompatible surfactants
  • biocompatible surfactants such as glycerol are believed to cause ice particles to shrink and become rounder and also serves as a cryo-protectant for non-lipid-rich cells.
  • Other exemplary biocompatible surfactants include sorbitan esters of fatty acids, polysorbates, polyoxyethylene sorbitan monooleate (also known as polysorbate 80 and available under the TWEEN® 80 trademark from Croda Americas LLC of New Castle, Del.), sorbitan monooleate polyoxyethylene sorbitan monolaurate (also known as polysorbate 80 and available under the TWEEN® 80 trademark from Croda Americas LLC of New Castle, Del.), polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan ester, polox
  • Surfactants can also act as a solvent, detergent, wetting agent, emulsifier, foaming agent, and/or dispersant.
  • Surfactants can be anionic, cationic, amphoteric, or nonionic.
  • Biocompatible surfactants can be included in injectable ice slurries.
  • Injectable slurries can be configured to have a desired temperature and to extract a desired amount of heat per unit of volume or mass of slurry.
  • the solute (i.e., freezing point depressant) concentration dictates the temperature of the slurry and the ice content of the slurry determines the amount of heat extracted by the slurry.
  • the slurry is preferably isotonic relative to the subject's cells, e.g., having an osmolarity of about 308 mOsm/L.
  • slurries including normal saline and 20% glycerol were able to target lipid rich cells while avoiding acute unselective necrosis.
  • Broadly destructive slurries can achieve colder temperatures and greater destructive power by increasing the solute concentration (e.g., to 20% w/v saline) to form a hypertonic solution (i.e., a solution having an osmolarity greater than about 308 mOsm/L) that will also disrupt cells through osmotic pressure. As the ice melts, the solute concentration will decrease.
  • solute concentration e.g., to 20% w/v saline
  • a hypertonic solution i.e., a solution having an osmolarity greater than about 308 mOsm/L
  • the injectable slurries can contain varying proportions of ice.
  • the slurries can contain between about 0.1% and about 75% ice by weight, between about 0.1% and 1% ice by weight, between about 1% and 10% ice by weight, between about 10% and about 20% ice by weight, between about 20% and about 30% ice by weight, between about 30% and about 40% ice by weight, between about 40% and about 50% ice by weight, between about 50% and about 60% ice by weight, between about 60% and about 70% ice by weight, and greater than about 50% ice by weight.
  • the proportions of ice by volume are slightly higher due to the densities of solid and liquid water.
  • the injectable slurry further comprises a therapeutic compound (which can be included in calculating the solute concentration above).
  • the therapeutic compound can be a liquid, a gas, or a solid.
  • the therapeutic compound is an anesthetic and/or an analgesic, for example, a water-soluble anesthetic (e.g., prilocaine), bupivacaine, prilocaine, tetracaine, procaine, mepivicaine, etidocaine, lidocaine, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids (e.g., methylprednisone), and the like.
  • a water-soluble anesthetic e.g., prilocaine
  • bupivacaine prilocaine
  • tetracaine e.g., procaine
  • mepivicaine etidocaine
  • lidocaine e.g., acaine
  • nonsteroidal anti-inflammatory drugs (NSAIDs) e.g., methylprednisone
  • an anesthetic in the slurry can be particularly advantageous when the slurry is used to provide a nerve block because (i) the effect of the anesthetic will provide immediate confirmation that the slurry is being injected in the correct location and (ii) the anesthetic can provide pain relief until the cyroneurolysis nerve block is effective (potentially after 48 hours).
  • the anesthetic is QX-314, N-ethyl bromide, a quaternary lidocaine derivative that is a permanently charged molecule capable of providing long term (over 24 hours) anesthesia.
  • QX-314 can provide more selective blocking of nociceptors and with longer duration of action and less side effects.
  • QX-314 is a charged molecule that needs to enter the cell and block the sodium channels intracellularly. The ability of QX-314 to block from the inside, but not the outside of neuronal membranes could be exploited to block only desired neurons. Combining QX-314 with the cold slurry injections described herein can selectively target cold sensing nociceptive sensory neurons to provide selective and long lasting anesthesia.
  • the therapeutic compound is a vasoconstrictor such as epinephrine, norepinephrine, other selective or nonselective adrenergic agonists, or a corticosteroid.
  • Vasoconstrictors can advantageously prolong the cooling effect of the slurry by reducing warming from blood flow. (Pressure or suction can also be used to reduce blood flow and/or isolate the target tissue as discussed in U.S. Pat. Nos. 7,367,341 and 8,840,608.)
  • the injectable slurry can include one or more lipolytic agents to enhance the reduction of lipid-rich cells.
  • lipolytic agents include biocompatible surfactants, bile salts and their derivatives (e.g., deoxycholic acid), phosphatidylcholine (lecithin), catecholamines, B-agonists (e.g., isoproterenol), alpha 2-agonists (e.g., yohimbine), phosphodiesterase inhibitors (e.g., aminophylline, theophylline), corticosteroids, caffeine, hyalorunidase, collagenase, alpha-tocopherol, ethanol, benzyl alcohol, carnitine, catechin, cysteine, gallic acid, laminarin, rutin, myrecetin, alpha MSH, melilotus, resveratrol, genistein, and the like.
  • Such agents can disrupt adipose tissue morphology when injected at room temperature and be particularly useful in augmenting disruption of adipose tissue morphology when included in slurries prepared for cryolipolysis and/or cryoneurolysis.
  • Table 3 provides a list of exemplary lipolytic agents, cell targets, and hypothesized mechanisms of action.
  • the injectable slurry further includes microbubbles or nanobubbles to aid in imaging (particularly by ultrasound) and verification of the injection site.
  • microbubbles and nanobubbles and methods for making the same are described in U.S. Pat. Nos. 7,897,141 and 8,715,622 and U.S. Patent Application Publication No. 2008/0247957, 2008/0279783, and 2009/0028797.
  • the slurry can further include a toxin or sclerosing agents such as ethanol, detergents, and the like.
  • Slurries can contain other emulsifiers and excipients included in other parenteral solutions such as those described in Sougata Pramanick et al., “Excipient Selection In Parenteral Formulation Development,” 45(3) Pharma Times 65-77 (2013). Exemplary excipients are listed in Table 4 below.
  • the substances described herein can be administered in a variety of doses that can produce varying effects. For example, low doses of a particular substance can act as an inert excipient, but exert a therapeutic effect at a higher concentration.
  • intralipid refers to an emulsion of lipids typically used for intravenous nutrition, e.g., an emulsion of 20% intravenous fat emulsion, 20% soybean oil, 1.2% egg yolk phospholipids (lecithin), 2.25% glycerin, water, and sodium hydroxide to adjust pH.
  • intralipid formulations are used in medicine.
  • additives include sugars, monosaccharides, disaccharides, oligosaccharides, polysaccharides, carbohydrates, lipids, anti-metabolites, oils, natural oils (e.g., canola, coconut, corn, cottonseed, flaxseed, olive, palm, peanut, safflower, soybean, and/or sunflower oil), peritoneal dialysis solution, ions (e.g., calcium, potassium, hydrogen, chloride, magnesium, sodium, lactate, phosphate, zinc, sulfur, nitrate, ammonium, carbonate, hydroxide, iron, barium, and the like), and the like.
  • oils e.g., canola, coconut, corn, cottonseed, flaxseed, olive, palm, peanut, safflower, soybean, and/or sunflower oil
  • ions e.g., calcium, potassium, hydrogen, chloride, magnesium, sodium, lactate, phosphate, zinc, sulfur, nitrate, ammonium, carbonate, hydroxide,
  • slurry with 5% TWEEN® 20 (polysorbate 20) in lactated Ringer's solution plus 5% dextrose initially had a regular slurry consistency, but became very foamy when reblended. Without being bound by theory, it is believed that foamy slurries can be formed with other detergents.
  • Foamy slurries or other biocompatible foams can be utilized as insulators to further protect adjacent tissue from cold-induced damage.
  • a foamy slurry or other biocompatible foam can first be injected adjacent to a cooling target (e.g., a nerve).
  • a slurry having a higher cooling power can then be injected adjacent to the target and within the foamy slurry or biocompatible foam as depicted in FIG. 24 .
  • the foamy slurry or biocompatible foam will act as an insulator, in part due to the entrained air, thereby protecting adjacent tissue from cold-induced damage and shielding the second slurry from warming by adjacent tissue.
  • Slurries can be prepared using a variety of methods.
  • a slurry is prepared using a commercially-available ice slurry generator such as those available under the MODUPAKTM DEEPCHILLTM trademark from Sunwell Technologies Inc. of Woodbridge, Ontario.
  • Commercially-available slurry generators include scraped surface generators that wipe away (e.g., with blades, augers, brushes) small ice crystals from a chilled surface and mix with water, direct contact generators in which an immiscible primary refrigerant evaporates to supersaturate the water and form small smooth crystals, and super cooling generators in which water is supercooled and released through a nozzle into a storage tank.
  • FIG. 1 depicts one exemplary method 100 of preparing a slurry.
  • ice is obtained.
  • the ice is preferably sterile ice and can either consist purely or essentially of water or can be a frozen mixture of water and one or more additives as discussed herein.
  • step S 104 one or more additives are optionally combined with the ice prior to processing.
  • the one or more additives are preferably at or near the desired slurry temperature in order to prevent melting and refreezing of the ice particles.
  • step S 106 the ice is processed into smaller pieces.
  • a blade grinder e.g., a blender, a food processor, and the like
  • Suitable blade grinders are available under the WARING® trademark from Conair Corporation of Stamford, Conn.
  • Suitable ice crushers and ice shavers are available under the CLAWSONTM trademark from the Clawson Machine Division of Technology General Corp. of Franklin, N.J. and under the SEMCOTM trademark from Semco Inc. of Pharr, Tex.
  • Suitable mills include the benchtop analytical mill available from Cole-Parmer of Vernon Hills, Ill. and depicted in FIG. 15 and can be utilized to mill either ice or dry ice.
  • ice particles can be formed by grinding/milling ice between surfaces (e.g., discs or screens) rotating in opposite directions.
  • shock waves, vibration e.g., ultrasonic vibration
  • thermal shock e.g., from lasers or steam jets
  • the ice (and any additives) can be placed in a bag and struck repeatedly with a mallet or other implement.
  • step S 108 one or more additives (e.g., glycerol) are added to crushed ice (and any previously added additives).
  • additives e.g., glycerol
  • ice can be scraped at ⁇ 80° C. into a biocompatible liquid cooled to 1° C. above the biocompatible liquid's freezing point.
  • a surfactant cooled to ⁇ 20° C. is then added and the resulting slurry is stirred vigorously.
  • FIG. 2 depicts another exemplary method 200 of preparing a slurry.
  • step S 202 sterile water is obtained.
  • Sterile water is available from a variety of sources including Hospira, Inc. of Lake Forest, Ill.
  • step S 204 one or more additives are optionally combined with the sterile water prior to processing.
  • step S 206 the water (and any additives) are frozen.
  • a variety of techniques and devices can be utilized to freeze the water.
  • One example is an ice cream maker that utilizes a moving element (either a paddle or a rotating vessel) to generate small ice crystals.
  • a moving element either a paddle or a rotating vessel
  • FIG. 3 An experimental prototype using a household ice cream maker is depicted in FIG. 3 .
  • small droplets of water are formed and then frozen.
  • Suitable devices for forming small droplets of water include atomizers, injectors, ejectors, aspirators, Venturi pumps, nebulizers, humidifiers, ultrasonic humidifiers, and the like.
  • the generated water droplets can be introduced into a cold environment that can be achieved, for example, using dry ice.
  • An example of ice produced by introducing droplets generated by an ultrasonic humidifier into a dry ice environment is depicted in FIG. 4 .
  • small droplets of water are dropped into liquid nitrogen then harvested. Ice balls 502 harvested using this technique are depicted in FIG. 5 .
  • This process can be automated through the use of a microdropper such as those available from microdrop Technologies GmbH of Norderstedt, Germany.
  • the slurry components can be provided pre-mixed liquid in a bag (e.g., an intravenous fluid bag and like) and then frozen within the bag under continuous or intermittent agitation, e.g., by shock waves, vibration (e.g., ultrasonic vibration), thermal shock (e.g., from lasers, steam jets), and the like to produce a slurry within the bag that can then be injected.
  • a bag e.g., an intravenous fluid bag and like
  • thermal shock e.g., from lasers, steam jets
  • a plurality of ice particles can be formed in a sub-millimeter (e.g., having a largest cross-sectional dimension of about 0.1 mm or less) or micro-scale casting mold as depicted in FIG. 28 .
  • the casting mold can be fabricated through molding, negative molding, 3D printing, additive manufacturing, machining, and the like to define receptacles of a variety of shapes and can be fabricated from a variety of materials such as polymers, plastics, elastomers, silicone, silicon, metals, and the like.
  • the tray can be provided pre-loaded with ice particles or can be loaded with water and frozen in a lab. The tray can flex to release the ice particles into a liquid component to form a slurry.
  • the casting can be performed by rapid cooling of the casting mold while in contact with liquid water or flowing of liquid water over or through the cold casting material, during which ice forms within casts. Ice particles can be removed from the casts by deformation of the casting material using mechanical strain, stress waves, or shock waves. Ice particles can be removed from the casts by partial melting from an external or internal energy source. Ice particles can be removed or aided to be removed from the casts by centripetal force, e.g., by centrifugation. For example, the casting mold can be rapidly rotated while cooled and periodically supplied with water in order to create small ice particles near the mold surface that are thrown off by centripetal force into a cold environment for collection.
  • Both the slurries described herein and precursor ice particles can be stable for years if held at stable humidity and temperature below the freezing point of the solution or the ice particles.
  • ice particles can be coated with a surfactant that acts as a barrier to sublimation and reduces friction between ice particles.
  • the ice particles and/or slurries can be stored under elevated pressure (e.g., above water's triple point).
  • Either method described above can be performed by a single actor at a single location at a single time or can be performed by one or more actors at one or more locations at one or more times.
  • small stable ice particles can be packaged and shipped using standard cold shipping methods and stored in a standard freezer (e.g., at ⁇ 20° C.).
  • the ice particles can be combined with one or more additional additives in the clinic shortly or immediately prior to injection.
  • the additives can, for example, be biocompatible solutions, contain a biocompatible surfactant such as glycerol, and be precooled (e.g., to a temperature approximating the desired temperature of the slurry at the time of injection).
  • the additives can be added through a variety of methods.
  • the ice particles are stored in a container such as a plastic bag such as those commonly used to store intravenous (IV) fluid and the additive is injected, pumped, or allowed to flow by gravity into the ice particles.
  • the additive is poured over the ice particles.
  • the additive is provided in frangible or burst pouch within the same container as the ice particles. This frangible or burst pouch can be squeezed to rupture the pouch and combine the additive and the ice particles at the desired time.
  • the temperature is preferably monitored to either maintain or achieve a desired temperature.
  • the slurry may need to rise to a desired temperature, but it may be preferred that the slurry does not rise significantly beyond a desired temperature.
  • Various thermometers, thermocouples, and other temperature measuring devices can be used to measure the temperature of the slurry. These measurements can be internal or external to the container holding the slurry.
  • a liquid crystal thermometer is applied to the outside of the container (e.g., an IV bag) holding the slurry. Suitable liquid crystal thermometers capable of measuring temperatures between ⁇ 30° C. to 0° C.
  • an additive in either the slurry or the container holding the slurry can change color to indicate an appropriate and/or inappropriate temperature.
  • a temperature monitor can be used to indicate inappropriate storage or transport conditions for the slurry.
  • an imaging technique such as ultrasound, magnetic resonance, x-ray, and the like can be utilized to verify the proper positioning of the injection device and/or the slurry.
  • ice is a very strong reflector of ultrasound, while lipid rich cells are poor reflectors of ultrasound.
  • Ultrasound imaging is a convenient “bedside” imaging modality with sufficient contrast and depth of imaging to guide and/or monitor administration of the slurry.
  • the injectable slurries described herein can be utilized to target all tissue types including, but not limited to, connective, epithelial, neural, joint, cardiac, adipose, hepatic, renal, vascular, cutaneous, and muscle tissues.
  • the injectable slurry advantageously can focus a cooling effect direct at the site of the targeted tissue without the challenges of diffusion of heat or perfusion tissue.
  • FIG. 6 a general method of treatment 600 using injectable slurries is provided. Although depicted in a linear manner, step(s) can be omitted, repeated, or executed in various orders.
  • the amount of heat to be extracted is determined.
  • the amount of heat to be extracted can be routine and predictable, particularly for treatment of small structures such as nerves and can be specified a priori, e.g., as part of approval of a medical device or procedure, as part of the instruction manual for a medical device, and/or as a preset control parameter in a medical device.
  • the amount of heat to be extracted can depend on the amount of tissue to be treated, the location of the treatment site, and other attributes of the subject.
  • treatment parameters are selected.
  • Treatment parameters can include the composition of the slurry (e.g., the ice content and additive content) and the temperature, which together (particularly the ice content) determine the cooling power of the slurry.
  • the additive content largely influences the temperature of the slurry.
  • Exemplary ice content and additive content is discussed herein.
  • Exemplary temperatures of the slurry include about +10° C., about +9° C., about +8° C., about +7° C., about +6° C., about +5° C., about +4° C., about +3° C., about +2° C., about +1° C., about 0° C., about ⁇ 1° C., about ⁇ 2° C., about ⁇ 3° C., about ⁇ 4° C., about ⁇ 5° C., about ⁇ 6° C., about ⁇ 7° C., about ⁇ 8° C., about ⁇ 9° C., about ⁇ 10° C., about ⁇ 11° C., about ⁇ 12° C., about ⁇ 13° C., about ⁇ 14° C., about ⁇ 15° C., between about ⁇ 15° C. and about ⁇ 25° C., between about ⁇ 25° C. and about ⁇ 50° C., between about ⁇ 50° C. and about ⁇ 75°
  • heat of fusion for lipids is about half of the heat of fusion for water and believes that about 2 units of fat volume can be treated with about 1 unit of slurry volume. It may be desirable to be conservative in the amount of slurry injected, particularly when the treatment site is proximate to nerves, blood vessels, organs, and the like.
  • the slurry is optionally allowed to reach the desired temperature. This can be achieved by allowing the slurry to sit at room temperature or in a controlled temperature environment until its temperature rises to the desired temperature.
  • the slurry can be optionally be stirred or agitated to promote an even temperature distribution.
  • the slurry can optionally be placed in an insulated container to preserve the slurry at the desired temperature.
  • the catheters, needles, and/or tubing used to deliver the slurry to the subject can optionally be insulated (e.g., with dead-air space or rubbers such as neoprene) to minimize temperature rise.
  • vasoconstriction is optionally applied, e.g., through physical means such as suction or pressure or chemical means such as epinephrine injections.
  • the application site is optionally pre-cooled to minimize melting of the slurry upon injection.
  • one or more thermoelectric (Peltier) cooling devices can be used to pre-cool tissue to a desired temperature prior to injection of a slurry. Suitable thermoelectric coolers are available from TE Technology, Inc. of Traverse City, Mich. and Quanta Aesthetic Lasers USA of Englewood, Colo.
  • step S 612 one or more cryoprotectant approaches can optionally be employed.
  • energy can be applied to tissue adjacent to the target tissue in order to protect the adjacent tissue from undesired cooling and/or enable more aggressive cooling of the target tissue.
  • Energy can be applied simultaneous with the slurry, in an oscillating manner, in response to feedback, and the like.
  • Suitable energy sources include radiofrequency (RF) energy generating units that can be adapted, configured, and/or programmed to generate monopolar, bipolar, capacitively-coupled, and/or conductively-coupled RF energy.
  • the RF energy can have a frequency between about 0.3 MHz and about 100 MHz.
  • Suitable energy sources include coherent light sources, incoherent light sources, heated fluid sources, resistive (Ohmic) heaters, microwave generators (e.g., producing frequencies between about 915 MHz and about 2.45 GHz), and ultrasound generators (e.g., producing frequencies between about 300 KHZ and about 3 GHz).
  • cryoprotectants e.g., glycerol, propylene glycol, and the like
  • the cryoprotectant can be applied topically to the epidermis and/or can be injected into a desired region.
  • an injection device is inserted into the subject.
  • suitable injection devices include hypodermic needles, cannulas, catheters, and the like.
  • the location and depth of insertion can vary to reflect the target region.
  • the injection device can be inserted to an appropriate depth for parenteral, subcutaneous, intramuscular, or interstitial injections.
  • step S 616 the location of the injection can be verified, e.g., through ultrasonic or x-ray imaging.
  • the slurry can be administered through a “blind” injection.
  • step S 618 a foamy slurry or biocompatible foam is optionally injected as described herein to insulate a later injected slurry.
  • step S 620 feedback about the injection is obtained.
  • Feedback can include additional imaging of the slurry, resistance to further injection, input from the patient (particularly when the slurry contains an anesthetic), information about the treatment site (e.g., using the feedback devices described in U.S. Pat. Nos. 7,367,341 and 8,840,608) and the like.
  • ice particles in the slurry are radiopaque and can be readily visualized using ultrasound.
  • step S 622 the slurry is injected.
  • Applicant has found that hand pressure typical of that provided to a syringe is sufficient for injection, but higher mechanical pressure can be used as well.
  • the slurry can be injected in discrete, pre-determined volumes or can be injected until a medical professional determines that the injection should cease, e.g., due to increased pressure or resistance to further injection or having injected a desired volume of slurry.
  • step S 624 feedback about the injection is obtained.
  • the slurry is optionally withdrawn, for example using the methods and devices described in U.S. Patent Application Publication No. 2013/0190744.
  • the suction can be applied concurrently, intermittently, and/or alternatingly to injection of a slurry.
  • a filtered or smaller gauge cannula can be inserted adjacent to or coaxial with an injection device as depicted in FIGS. 27A-27C to remove melted fluid during a procedure while leaving most or all of the ice particles in the injection site.
  • Such an embodiment can be particularly useful for anatomically constrained targets such as nerves in which injecting large volumes of slurry poses challenges.
  • step S 628 the injection device is removed from the injection site.
  • step S 630 the injection site is assessed. Assessment can be performed during or after the procedure to assess the effect of the injected slurry. Assessment can be performed by a medical professional and/or by the subject and can include self-reporting, photography, calipers, MRI, as well as the imaging devices described in U.S. Pat. Nos. 7,367,341 and 8,840,608.
  • All or portions of this method can, but need not, be repeated one or more times for the same injection site and/or target tissue. Multiple injections can be performed in a serial, overlapping, or parallel manner.
  • the cryoslurry is injected at a sufficient volume to cause tumescent swelling of the injection site.
  • a plurality of injection sites each receive an effective amount of slurry for treating a small region of tissue.
  • injections of substantially uniform volumes of slurry can be made in a grid or other pattern.
  • serial injections are made within a single treatment session.
  • a first injection can be made to pre-cool the area before a second injection is made to achieve the desired clinical or cosmetic cooling effect.
  • the formulation of these serial injections can vary.
  • the second injection can have a higher or lower cooling power than the first injection.
  • a major limitation of medical nerve blocks is their limited duration, which last for hours but not even one day. When somewhat longer relief of pain is needed, constant or repeated infusions of anesthetics are sometimes performed through a needle or through an indwelling catheter, but typically chronic pain is the setting for use of potent analgesics such as opiates, with associated high risk of side effects including addiction.
  • cold and particularly slurries can be used to provide long-term, but reversible inhibition of nerve function.
  • the slurries described herein can provide unprecedented long-lasting reduction or full relief of pain, regardless of its cause.
  • Methods of the invention can also be used to reduce or eliminate symptoms associated with pain disorders caused by surgery, such as any surgery that makes an incision through the skin and induces pain.
  • the slurry can be injected prior, during or after incision.
  • Methods of the invention can also reduce or eliminate symptoms associated with motor disorders including, but not limited to, hemifacial spasm, laryngospasm and gustatory hyperhidrosis. Methods of the invention can also be used to reduce muscle spasms caused by aberrant nerve firing such as bladder or facial spasms. Methods of the invention can also be used to target motor nerves if prolonged paralysis of a motor nerve is desired.
  • the solution comprising the slurry can be administered to the peripheral nerves of the subject by injection, infusion or tumescent pumping of the slurry into a nerve or nerves such as peripheral, subcutaneous or autonomic nerves of the subject by injection into a nerve or nerves selected from the group consisting of the cutaneous nerve, trigeminal nerve, ilioinguinal nerve, intercostal nerve, interscalene nerve, supraclavicular nerve, infraclavicular nerve, axillary nerve, pudendal nerve, paravertebral nerve, transverse abdominis nerve, lumbar plexus nerve, femoral nerve, and sciatic nerve.
  • a nerve or nerves such as peripheral, subcutaneous or autonomic nerves of the subject by injection into a nerve or nerves selected from the group consisting of the cutaneous nerve, trigeminal nerve, ilioinguinal nerve, intercostal nerve, interscalene nerve, supraclavicular nerve, infraclavicular nerve, axillary nerve, pu
  • Methods of the invention can also reduce or eliminate pain associated with a nerve plexus (i.e., a group of intersecting nerves) including but not limited to the cervical plexus that serves the head, neck and shoulders, the brachial plexus that serves the chest, shoulders, arms and hands, the lumbar plexus that serves the back, abdomen, groin, thighs, knees, and calves, the sacral plexus that serves the pelvis, buttocks, genitals, thighs, calves, and feet, the celiac plexus (solar plexus) that serves internal organs, the coccygeal plexus that serves a small region over the coccyx, the Auerbach's plexus that serves the gastrointestinal tract and Meissner's plexus (submucosal plexus) that serves the gastrointestinal tract.
  • a nerve plexus i.e., a group of intersecting nerves
  • a nerve plexus i.e.,
  • Methods of the invention can also be used for renal sympathetic denervation, which is an emerging therapy for the treatment of severe and/or resistant hypertension.
  • Injecting a physiological slurry around a particular sensory nerve specifically blocks conduction of that nerve, leading to sensory losses in the entire distribution of the target nerve.
  • slurry injection can relieve pain and/or itch over a very large region of skin, muscle, joints, and the like that are “served” by a particular target nerve.
  • cooling can also block motor nerves.
  • Many nerves in the human body have mixed sensory and motor function.
  • the anatomy of the peripheral nervous system is such that the motor and sensory nerve fibers become fully separated near the spine.
  • a prolonged and specific block of sensory functions associated with spinal nerve level(s), can be obtained by prolonged block of the sensory nerve root using slurry injection.
  • Slurry injection, with or without ultrasound guidance, to the sensory portion of the peripheral nerve can provide prolonged, specific relief of pain.
  • the step of injection for slurry is similar to injection of medical anesthetic nerve blocks.
  • slurries described herein can be utilized to provide long-term, but reversible inhibition of the autonomic sympathetic nerves adjacent to the renal artery to treat hypertension.
  • Other exemplary nerve targets include the sympathetic and parasympathetic nerves.
  • the slurries described herein can be utilized to provide selective reduction of lipid-rich cells.
  • Slurry injection provides several improvements over cryolipolysis using external cooling device for subcutaneous fat reduction, due, in part, to the high cooling power of injectable slurries.
  • slurry injections can avoid the epidermis and dermis and approaches that are commercially utilized to detect epidermal temperatures and protect against damage to non-lipid-rich cells.
  • the dermis and/or epidermis will remain within 15° C. of normal physiological temperature during most subcutaneous slurry injections into adipose tissue.
  • warming of the skin can be performed, e.g., by application of a warm object or by radiant heating.
  • slurry injection is not limited for depth or location of treatment. Slurry can be injected superficially, deeply, or throughout the subcutaneous fat layer and is not limited by the geometries of the subject's skin and the topical applicator.
  • slurry injection can be done with greater anatomic accuracy. Physicians are generally very skilled at performing injections, even without ultrasound guidance.
  • slurry can be placed with high accuracy.
  • the slurry itself can be visualized by ultrasound, such that the treated tissue is well-defined and known during treatment.
  • slurries can be administered without the use of large thermoelectric devices used in commercial cryolipolysis systems.
  • Slurry injections can also quickly numb the nerves adjacent to the treatment site(s), potentially eliminating or reducing the use of anesthesia used in commercial cryolipolysis procedures.
  • cryolipolysis can be achieved through injections of slurries at temperatures of about +5° C. and lower.
  • higher ice content slurries will be most effective in extracting sufficient heat to achieve cryolipolysis in clinically and/or cosmetically significant numbers of adipose cells.
  • slurries having at least about 50% ( ⁇ 30%) ice by weight may be preferred.
  • the slurry includes an effective amount of a lipolytic agent such as those described herein.
  • the amount of slurry and/or the slurry ice content to be injected can be calculated and calibrated to produce a desired amount of cryolipolysis. Without being bound by theory, it is believed that cooling effects of slurries can be tightly controlled such that two slurries having the same composition and physical characteristics will produce substantially the same amount of cryolipolysis if injected into the same location under the same physiological conditions.
  • the slurries described herein can be utilized to achieve cooling rates above about ⁇ 2° C. per minute.
  • the cooling rate can be greater than about ⁇ 10° C. per minute, greater than about ⁇ 20° C. per minute, greater than about ⁇ 30° C. per minute, greater than about ⁇ 40° C. per minute, greater than about ⁇ 50° C. per minute, greater than about ⁇ 60° C. per minute, greater than about ⁇ 70° C. per minute, greater than about ⁇ 80° C. per minute, greater than about ⁇ 90° C. per minute, greater than about ⁇ 100° C. per minute, greater than about ⁇ 110° C. per minute, greater than about ⁇ 120° C.
  • Cryolipolysis via slurry injection can be applied to variety of regions in which fat reduction is desired for medical and/or cosmetic reasons. Exemplary regions include the abdomen, flanks (also known as “love handles”), buttocks, thighs, arms, neck, chin (e.g., treatment of submental fullness also known as a “double chin”), and the like.
  • Sleep apnea is due to upper airway obstruction during sleep. Sleep apnea causes poor quality sleep, wakening, organ damage from hypoxia (including myocardial infarctions, stroke, and cumulative brain injury), and is a frequent cause of death in obese individuals. The prevalence of sleep apnea has been steadily increasing in the US due to obesity. Present treatments are generally aimed at reducing the degree of obesity (through diet, exercise, medications, and/or surgery) and at keeping the airway open during sleep. Continuous positive airway pressure (CPAP) helps to keep the airway patent, but requires wearing a close-fitting mask and pressure apparatus all night. These often fall off during sleep, leak, or are uncomfortable enough that sleep can be disrupted simply by wearing them.
  • CPAP Continuous positive airway pressure
  • Occlusion of the airway is strongly related to the amount of fat located in deep fat pads located at the base of the tongue and along the soft palate and lateral pharynx.
  • Surgical procedures have been developed, for example, to suspend the palate or debride pharyngeal fat, but these ultimately also cause scarring, often fail to open the airway sufficiently, are painful and cause local edema during healing that can precipitate worse sleep apnea, airway obstruction, respiratory distress and death.
  • Injection of physiological ice slurry into the subglottal, palatal and/or pharyngeal fat is a novel treatment for sleep apnea.
  • Guidance by ultrasound for accurate placement and injection of slurry within the target tissue is also a novel method.
  • These fat compartments are distinct from subcutaneous fat. They can be visualized by ultrasound, as regions of echolucency (low signal) compared with surrounding muscle, fascia and other structures. Slurry with a high ice content is particularly desirable to minimize the volume of injected slurry needed for effective reduction of the target fat.
  • injection of slurry into the fat will induce gradual reduction in the amount of fat, resulting in improvement or cure of the patient's sleep apnea.
  • the intrinsic selectivity of this treatment for fat is such that adjacent muscle, fascia, salivary gland and other tissues are spared from injury, while reliable reduction of the target fat can be achieved. Unlike surgery, this would be an office procedure performed with little or no anesthesia. Unlike surgery, there would be no scarring because the treatment is intrinsically selective for the lipid-rich adipose tissue causing sleep apnea. The post-treatment pain, inflammation and risk of airway compromise will be less than surgical procedures, because adjacent tissues are not affected. Unlike CPAP, injection of physiological ice slurry provides a permanent improvement and does not interfere with sleep.
  • Exemplary regions that can be targeted include the anterolateral upper airway, pharyngeal fat pads (for example, fatty deposits in the laryngopharynx, nasopharynx, oropharynx, and palatopharynx), parapharyngeal fat pads (for example, fatty deposits in the retropalatal and retroglossal regions), fat located within the tongue (e.g., within the posterior tongue), and soft palate.
  • pharyngeal fat pads for example, fatty deposits in the laryngopharynx, nasopharynx, oropharynx, and palatopharynx
  • parapharyngeal fat pads for example, fatty deposits in the retropalatal and retroglossal regions
  • Injections can be made through the mouth or through the neck in order to best target a particular region of fat while avoiding adjacent nerves, blood vessels, and other structures.
  • the amount of fat removed per treatment can be adjusted by adjusting the volume and/or ice content of the injected slurry, and precise location of the fat removed can be adjusted by location of the injection(s).
  • Multiple courses of treatment that each remove a small volume of fat from fat located in the tongue, neck, palate, pharynx and/or tonsil may be preferred in order to minimize temporary airway constriction due to the added slurry volume.
  • This novel method for treatment of sleep apnea can have a major impact on health care, including reducing the morbidity, heart attacks, stroke and death associated with obesity.
  • a spinal cord lipoma is fat within the normally positioned spinal cord without any skin or bony abnormalities. These lesions are most commonly located within the thoracic spinal cord. Although rare, these lesions can cause severe morbidity. They may be symptomatic and appear most often in adults. Patients can present with spinal cord compression that can cause numbness and tingling, weakness, difficulty with urinating or bowel movements, incontinence, and stiffness of the extremities.
  • the current treatment for symptomatic lipomas around the spinal cord is a laminectomy to gain access to the spinal cord.
  • the goal of surgery is to reduce the size of the lipoma, not total removal of the fat. No other treatment method is recommended.
  • Embodiments of the invention utilize injection of cold slurry to specifically target the spinal lipomas without the need to do laminectomy as cold slurry could be directly injected into the lipoma through a needle. With the use of ultrasound guidance, the lipoma can be located and specifically destroyed via a cold slurry injection. This novel method of treating lipomas will reduce the morbidity associated with surgical procedures
  • the slurry injection method of treatment can be used for any lipomas around the nerves including peripheral nerves. Lipomas may also grow near or surrounding important peripheral nerves. Therefore, their removal can cause nerve injury and possible paralysis. Common locations include the neck, buttock, and forearm. Again, injection of the slurry into the lipomas to selectively target them will reduce the need for surgery.
  • Lipomyelomeningocele is a common and severe closed neural tube defect in children. Lipomyelomeningocele lies within the spectrum of closed neural tube defects. It represents a complex disorder that may present with neurological deficits secondary to the inherent tethered cord. This is a lesion present at birth that is commonly associated with spina bifida (congenital failure of the spinal bones to close). The condition is associated with abnormal fat accumulation that starts below the skin and extends through the bony opening to the spinal cord. These lesions become evident within the first few months to years of life and affect females more than males in a 1.5 to 1 ratio. More than 90 percent of patients will have an obvious soft tissue swelling over the spine in the lower back.
  • Injection of cold slurry can specifically target the lipoma and decrease its size, thus preventing neurological damage associated with their growth.
  • the injection needle can be guided by ultrasound or MRI (magnetic resonance imaging) for accurate placement and injection of slurry within the target tissue.
  • MRI magnetic resonance imaging
  • MRI magnetic resonance imaging
  • the use of slurry to treat LMM will offer a novel, less morbid and lifesaving treatment for these pediatric patients.
  • Pseudogynecomastia or lipomastia in males is due to the presence of fat deposits in the breast. This condition is more prevalent in men with aging, overweight, certain drugs, or exposure to estrogens including dietary sources. Currently, surgical removal is the preferred treatment. Applicant believes that injection of embodiments of the slurries described herein into the excess fat around the breast tissue will be less invasive technique with less morbidity.
  • slurry injections can be used for female breast reduction procedures, particularly, as a substitute to liposuction-only techniques indicated for minor-to-moderate volume reduction.
  • the increase in connective tissue discussed in greater detail herein also can provide a firming and lifting effect to either the breast or pectoral region.
  • the slurries described herein can be utilized to treat epicardial and/or pericardial fat. Such treatments can be used for the prevention of coronary artery disease and coronary atherosclerosis, prevention and treatment of atrial fibrillation and atrial tachyarrhythmias, and prevention and treatment of ventricular tachyarrhythmia.
  • Thoracic fat includes extra-pericardial (outside the visceral pericardium) and intra-pericardial (inside the visceral pericardium) adipose tissue. It is called ectopic adipose tissue although it is a normal anatomical structure. Intra-pericardial adipose tissue, which is predominantly composed of epicardial and pericoronary adipose tissue, has a significant role in cardiovascular system function. The epicardial fat is located between the myocardium and visceral pericardium and the pericardial fat, is located outside the visceral pericardium and on the external surface of the parietal pericardium. Epicardial and pericardial fat are embryologically different.
  • Pericardial fat may represent an important risk factor for cardiovascular disease because of its unique properties and its proximity to cardiac structures. Pericardial fat has been associated with an adverse cardiovascular risk profile, coronary artery calcium, and prevalent cardiovascular disease in several studies. Pericardial fat volume (PFV) has recently been reported to be strongly associated with CAD severity and presence. Pericardial fat has also been associated with common arrhythmias, such as atrial fibrillation (AF). AF is the most common cardiac arrhythmia in clinical practice and is associated with major morbidity and mortality. AF prevalence has been projected to increase in the coming decades and is expected to affect over 7.5 million Americans by the year 2050. Pericardial fat has also been associated with ventricular tachyarrhythmia and mortality from systolic heart failure.
  • AF atrial fibrillation
  • the slurries described herein can be utilized to treat epicardial and/or pericardial fat by injection of slurry into and/or around pericardial and/or epicardial fat during cardiac surgery. Additionally or alternatively, computed tomography (CT) or ultrasound (US) imaging can be utilized to guide a needle into the pericardial and/or epicardial fat for slurry injections. Injections can also be performed under direct vision of video-assisted thorascopic surgery.
  • CT computed tomography
  • US ultrasound
  • slurry can be injected into the pericardium with or without the use of ultrasound guidance.
  • the main approaches to accessing the pericardium are subcostal, parasternal and apical.
  • pericardiocentesis can be performed using a long, thin needle or catheter (e.g., 7-9 cm, 18 G).
  • a long, thin needle or catheter e.g., 7-9 cm, 18 G.
  • this space can hold a volume of up to 200 ml without hemodynamic compromise and can hold more than 500 ml if fluid accumulates chronically.
  • the slurries described herein can be utilized to provide selective reduction of lipid rich cells such as visceral fat in accordance with the methods described in U.S. Patent Application Publication No. 2013/0190744.
  • the slurries described herein can be introduced into the abdominal and/or peritoneal cavity. Such injections can reduce lipid-rich cells in structures such as the omentum and the perinephrium and regions such the perigonadal, retroperitoneal, and mesenteric regions of the body.
  • embodiments of the slurries described herein can be utilized in traditional cryoablation techniques including prostate cryoablation, renal cryoablation, cardiac cryoablation, fibroadenoma cryoablation, and the like.
  • Traditional cryoablation is performed with various invasive probe devices at very low temperatures, typically about ⁇ 30° C. to ⁇ 100° C. Tissue destruction is not selective for lipid-rich cells at these temperatures.
  • An injected slurry with high osmolality and high ice content can achieve temperatures below ⁇ 20° C., and could be used for these non-selective procedures, with some advantages over existing cryogen probe devices.
  • adipose tissue is a connective tissue, but it tends to become lax.
  • Slurry injection removes the adipocytes, but preserves and stimulates the septae, resulting in less laxity and greater mechanical support. Histology and also gross images such as FIGS. 13A and 13B clearly show that slurry injection into adipose tissue causes this change.
  • This effect provides an added benefit to procedures such as cryolipolysis, breast reduction, and treatment of obstructive sleep apnea, pseudogynecomastia, and lipomastia, but can be used for the sole purpose of skin tightening.
  • the pelvic floor is the supportive apparatus that holds the pelvic organs in place.
  • Pelvic floor dysfunction e.g., due to pelvic floor laxity
  • slurries and methods described herein can be applied to strengthen and/or tighten the pelvic floor.
  • slurries can be injected (e.g., through transurethral, transvaginally, or transperitoneal injections) adjacent to the pelvic floor to induce tightening and/or thickening of the pelvic floor in order to better support one or more pelvic organs.
  • the invention provides a method for treating stress urinary incontinence in a subject in need thereof.
  • the method comprises administering to the connective tissue of the pelvic floor of the subject a therapeutically effective amount of a slurry described herein.
  • urgency incontinence is due to overactivity of the detrusor muscle.
  • the slurries described herein can be used as an injectable therapy to inhibit neural input to the bladder.
  • Abdominal laxity can lead to hernias or cosmetically bothersome abdominal protrusions.
  • the slurries described herein can be used to cause skin tightening and/or tightening of the fascia supporting the abdominal wall to prevent and/or remedy hernias or abdominal protrusions.
  • Heat capacity is an important component of the heat exchange between a slurry and a tissue.
  • the first heat exchange to consider is that of the energy stored by the heat capacity of slurry and tissue.
  • H energy density
  • T temperature
  • ⁇ density
  • C specific heat capacity
  • T m f s T s +(1 ⁇ f s ) T t
  • the volume fraction of ice in a physiological slurry in this model is defined as I s , being the volume of ice per unit volume of slurry.
  • I s the volume fraction of ice in the local slurry-tissue mix.
  • I o is the total amount of ice available for melting, per unit volume of the slurry-tissue mix.
  • ice in the slurry component of the slurry-tissue mix begins to melt, absorbing heat and cooling the slurry-tissue mix. Ice in the slurry-tissue mix melts until it is gone, or until an equilibrium temperature is reached, before the period of gradual warming by body heat exchange briefly discussed above.
  • ice and liquid water can co-exist at equilibrium temperatures between 0° C. and 4° C.
  • tissue there are numerous solutes that cause freezing point depression, such that ice and water co-exist over a somewhat lower temperature range, e.g., about ⁇ 8° C. to 0° C. in skin. Lipids in the tissue are in a liquid state at normal body temperature.
  • lipids can crystallize.
  • These two processes proceed in opposite directions (e.g., the water melts, the lipids crystallize) because lipid crystallization occurs at temperatures considerably higher than the freezing point of water.
  • Most animal fats crystallize at between 10° C. and 15° C., depending on the length and saturation of the lipid chains in triglyceride molecules.
  • Wax esters and free fatty acids crystallize at similar temperatures.
  • Polar lipids crystallize at lower temperatures, for example the phospholipids of cell membranes can remain somewhat fluid even well below 0° C.
  • Injected physiological slurries are effective to inhibit pain or itch by affecting nerve myelin sheath lipids. Lipids of the sheath crystallize well above 0° C. Effective treatment depends on variables including the starting tissue temperature T t , the ice content of slurry I s , the amount and speed of slurry injected to achieve an adequate slurry fraction f s in the slurry-tissue mix, the target lipid content of the tissue L t , its crystallization temperature T c , and the time for which some ice remains in the slurry-tissue mix.
  • Enthalpy of fusion also called heat of fusion
  • heat of fusion describes how much thermal energy is absorbed (endothermic) or released (exothermic) due to changing from solid to liquid state.
  • the melting of ice is an endothermic transition requiring a large amount of thermal energy.
  • the heat of fusion is 80 cal/gm.
  • the density of ice at 0° C. is 0.92, such that the volumetric heat of fusion, H ice (the heat energy needed to melt a volume of ice) is:
  • Typical values as mentioned above for f s range from about 0.2 to 0.8, and the ice content of physiological slurry can be up to about 50% (I s ⁇ 0.5).
  • the range (without limitation) for Q icetotal in the slurry-tissue mix is therefore about 7 to 30 cal/cm 3 .
  • the heat of fusion for animal fat lipids ranges from about 30-50 cal/gm.
  • the density of lipids range from about 0.8-0.9 gm/cm 3 (e.g., palmitic triglyceride in solid phase is 0.85 gm/cm 3 ).
  • the latent heat per unit volume for crystallization of lipids is about:
  • H lipid 34 cal/cm 3 .
  • the latent heat for crystallization of lipids is less than half of that for melting of ice. Cooling of the slurry-tissue mix proceeds by some ice melting, until the temperature reaches about 10° C., the temperature necessary for lipid crystallization to begin.
  • the thermal energy from consumed by dropping the temperature of the slurry-tissue mix to about 10° C. is given by:
  • the lipid content of the slurry-tissue mix is therefore another important factor. Defining the lipid content of the tissue as f tlip , the lipid content of the slurry-tissue mix is:
  • f mlip (1 ⁇ f s ) f tlip .
  • f tlip depends on tissue type.
  • the energy per unit volume of the slurry-tissue mix that is produced by crystallizating all of the lipid present, is:
  • the lowest temperature reached is determined by heat exchange between the residual ice melting, and the heat capacity of the slurry-tissue mix.
  • the lowest temperature T final can therefore be estimated by equating the latent heat per unit volume absorbed by melting of the residual ice, with the heat associated with heat capacity of the temperature drop below about 10° C.
  • I residual Q iceresidual H ice .
  • the temperature drop to T final due to residual ice melting can be estimated by: Q iceresidual ⁇ (10 ⁇ T final ) ⁇ C, which rearranges to
  • the local heat exchanges modeled above occur over a time scale of seconds because the slurry is intimately in contact with tissue, by mixing flowing and/or dissecting through the soft tissue during interstitial injection.
  • the temperature of the slurry-tissue mix settles at about T final , then gradually warms due to conduction and convection.
  • the rate of gradual warming depends therefore on the rates of conduction and convection. In the absence of blood flow (convection), warming by conduction involves a minimum characteristic time, proportional to the square of the diameter of the local slurry-tissue mix.
  • the time in seconds for substantial warming of a region by conduction is approximately equal to the square of the diameter in millimeters.
  • a 10 mm diameter slurry-tissue mix would typically necessitate about 100 seconds for substantial warming
  • a 30 mm diameter slurry-tissue mix would typically necessitate about 900 seconds (i.e., 15 minutes) for substantial warming by conduction.
  • some ice may remain even after this estimated period of substantial warming.
  • the model presented here is illustrative, not exact. Direct measurement of slurry and tissue temperatures can be performed. As shown below, such measurements are generally consistent with this approximate model.
  • Applicant tested the ability of a sterile, cold injectable slurry to reduce the temperature of adipose tissue.
  • FIG. 7 depicts an ice slurry with a high concentration of small ice particles that can be easily injected via a 15-19 gauge needle into the subcutaneous fat tissue.
  • FIGS. 8A-8C depict the results of injection of an ice slurry into human abdominoplasty adipose tissue. Ice crystals 802 are clearly visible in the adipose tissue.
  • Slurry has many times (typically 5-8 times, depending on the ice content) the cooling capacity of liquid coolants (such as cold saline) and is, therefore, able to extract much more thermal energy to selectively damage lipid rich tissue such as fat.
  • liquid coolants such as cold saline
  • embodiments of the sterile and biocompatible slurries described herein generate a target tissue temperature of ⁇ 3° C. to ⁇ 2° C. Damage to the target lipid-rich tissue tends to be enhanced when the cooling rate is high at least in part because of limited time for various protective tissue responses.
  • tissue temperatures in the ⁇ 3° C. to ⁇ 2° C. range were produced nearly instantaneously as depicted in FIG. 10 .
  • FIG. 10 depicts the results of injection of slurry into ex vivo human abdominoplasty specimen.
  • a 38° C. heating pad was placed underneath the specimen to provide constant heat mimicking human core temperature.
  • the slurry was injected into human fat tissue using a 60 ml syringe and 15 gauge needle with the starting fat temperature of 23° C. as measured by a thermocouple embedded into the adipose tissue.
  • the temperature of the adipose tissue decreased immediately down to ⁇ 3° C.
  • tissue temperature in the tissue immediately adjacent to the slurry is maintained at or below 0° C. until all of the ice has melted.
  • a single slurry injection was able to maintain it below 0° C. for at least 10-15 minutes.
  • the low temperatures generated by injected slurry causes localized and selective damage to lipid-rich target tissue such as adipose tissue and myelinated nerves.
  • Applicant conducted experiments injecting physiological sterile ice slurry into the subcutaneous fat of live swine. In this controlled study, the effects of slurry injections were compared with injection of melted slurry and of normal saline at other sites in the same animal. Injections were performed in accordance with an approved animal study under general anesthesia.
  • Applicant generated sterile biocompatible slurry with a temperature at injection ranging from +1° C. to ⁇ 3° C. Prior to injection, ultrasound measurements and standardized photographs were obtained of the sites that were to be injected in swine. Sites were injected with cold slurry, room temperature melted-slurry (a solution without ice), water, or normal saline. Another control site was not injected and received brief skin cooling only. A 15 gauge needle was used, however, Applicant confirmed in other experiments that the same slurry composition is injectable through a 19 gauge needle.
  • Sites were injected through the skin only into an area of approximately 4 cm ⁇ 4 cm. Approximately 20 cc of cold or room temperature slurry and saline control were successfully delivered to the subcutaneous fat of predestinated sites.
  • the temperature inside the injection site was as cold as ⁇ 2° C.
  • the duration of cooling (defined as the period in which the temperature of the treatment site remains below +5° C.) ranged from approximately 5 to 19 minutes.
  • injection sites demonstrated obvious depression on gross inspection at the sites where cold slurry was injected as depicted in FIGS. 11B, 13A, and 13B corresponding to loss of subcutaneous fat. In contrast, there was no apparent depression at the sites where room temperature slurry, water, and saline were injected. It is important to note that on gross examination there was no sign of any damage to surrounding skin tissue. In addition, there was no sign of infection or nonspecific damage to the sites.
  • FIGS. 12A and 14A Ultrasound images of the sites at baseline ( FIGS. 12A and 14A ) and at 4 weeks after the injection ( FIGS. 12B and 14B ) clearly demonstrate approximately 40-50% loss of superficial subcutaneous fat tissue only in the sites injected with cold slurry.
  • FIGS. 20A and 20B further experiments were conducted on another pig using normal saline plus 10% glycerol slurry, room temperature (melted) slurry, both with and without precooling.
  • FIG. 20A depicts injection sites before injection and
  • FIG. 20B depicts injection sites 14 days after injection.
  • FIG. 21 depicts a graph of cooling at three points.
  • T3 represents the temperature of adipose tissue inside the pocket of slurry injection.
  • T2 represents the temperature of adipose tissue adjacent to the pocket of slurry injection.
  • T4 represents the temperature of skin adjacent to the pocket of slurry injection.
  • FIGS. 22A-22D are photographs of injection site 11, which received an injection of normal slurry with 10% glycerol at ⁇ 4.1° C.
  • FIGS. 22A and 22B depict the site pre-injection while FIGS. 22C and 22D depict the prominent depression 8 weeks post-injection.
  • thermal smoothing refers to allowing a slurry to partially melt prior to injection. Ice particles in a slurry freshly made by mechanically pulverizing ice, have various polygonal shapes, similar to the gravel produced when rock is pulverized. Such particles tend to interlock, limiting flowability.
  • Partial melting produces more rounded ice particles, and a slurry with greater flowability for a given particle size and ice content.
  • Other methods to improve flowability include using smaller ice particles, lower ice content, adding solute and/or surfactants prior to use of the slurry. Both isotonic and hypertonic solutions were shown to be capable of inducing fat loss. Additionally, slurries containing colloid solutions such as 6% hetastarch in Lactated Ringer's solution are capable of inducing fat loss as seen in Sites 23 and 25.
  • FIG. 25A depicts the injection site.
  • FIG. 25B depicts the injection depth.
  • FIGS. 25C and 25D depict the localization of the slurry (containing ink) within the parapharyngeal fat pads.
  • FIGS. 31A and 31B provides images of gross biopsies taken at time of sacrifice three months post-procedure.
  • FIG. 31A is a cross-section of tissue at a site injected with with a cold slurry of normal saline+10% glycerol.
  • FIG. 31B is a cross-section of tissue at a site injected with a room temperature solution of normal saline+10% glycerol.
  • dermal thickening of 38.1% was noted at the time of sacrifice.
  • the site receiving a room temperature solution of the same composition as slurry shown in FIG. 31A did not show any change in the thickness of the dermis.
  • FIGS. 32A and 32B provide images of histology taken at time of sacrifice three months post-procedure and stained with hematoxylin and eosin (H&E).
  • H&E hematoxylin and eosin
  • FIGS. 34A and 34B provide images of immunohistochemical (IHC) staining for type I collagen taken at time of sacrifice three months post-procedure.
  • FIGS. 35A and 35B provide images of immunohistochemical (IHC) staining for type III collagen taken at time of sacrifice three months post-procedure.
  • Rats were injected with a variety of slurry formulations detailed in Table 7 to assess safety and tolerability of the slurries. All of the animals tolerated the injection with no sign of infection, ulceration, necrosis or side effects.
  • slurry compositions were tested in this experiment: (a) 6% hetastarch in lactated Ringer's solution, (b) 5% TWEEN® 20 (polysorbate 20) in lactated Ringer's solution plus 5% dextrose and (c) 5% polyethylene glycol (PEG) in lactated Ringer's solution plus 5% dextrose.
  • Lactated Ringer's solution is a commonly used intravenous fluid that is isotonic. It is composed of 120 mEq sodium ions, 109 mEq chloride ions, 28 mEq lactate, 4 mEq potassium ions, and 3 mEq calcium ions. Thus, it differs from normal saline in its composition.
  • FIGS. 17A and 17B depict the result of injections of 6% hetastarch in lactated Ringer's solution at room temperature (+15.4° C.) and cold slurry (+0.3° C.), respectively.
  • FIG. 17C depicts the control (not injected) side.
  • FIGS. 17D-17G depict tissue surrounding the injection site demonstrating no effects on muscle or surrounding tissue.
  • FIGS. 18A and 18B depict the result of injections of 5% TWEEN® 20 (polysorbate 20) in lactated Ringer's solution plus 5% dextrose at room temperature (+16° C.) and cold slurry ( ⁇ 0.6° C.), respectively, in adult Sprague-Dawley rats.
  • FIG. 18C depicts the control (not injected) side.
  • FIGS. 18D-18G depict tissue surrounding the injection site demonstrating no effect on muscle or surrounding tissue.
  • FIGS. 19A and 19B depict the result of injections of 5% polyethylene glycol (PEG) in lactated Ringer's solution plus 5% dextrose at room temperature (+8° C.) and cold slurry ( ⁇ 0.8° C.), respectively, in adult Sprague-Dawley rats.
  • FIG. 19C depicts the control (not injected) side.
  • FIGS. 19D-19G depict tissue surrounding the injection site demonstrating no effect on muscle or surrounding tissue.
  • FIGS. 29A and 29C The histology of the perigonadal visceral fat at time of sacrifice in the warm saline group is shown in FIGS. 29A and 29C and the histology at the time of sacrifice in the slurry group is shown FIGS. 29B and 29D , respectively.
  • FIGS. 29A and 29C The histology of the perigonadal visceral fat at time of sacrifice in the warm saline group. 29A and 29C and the histology at the time of sacrifice in the slurry group is shown FIGS. 29B and 29D , respectively.
  • FIGS. 29A and 29C The histology of the perigonadal visceral fat at time of sacrifice in the warm saline group is shown in FIGS. 29A and 29C and the histology at the time of sacrifice in the slurry group is shown FIGS. 29B and 29D , respectively.
  • FIGS. 29A and 29C The histology of the perigonadal visceral fat at time
  • 29A and 29C show normal visceral fat morphology in the warmed normal saline group. However, disruption of fat morphology is observed in the saline slurry group depicted in FIGS. 29B and 29D , on both gross histology and high magnification, respectively.
  • mice were taken from a larger cohort, anesthetized, weighed, and each administered a 2 cc intraperitoneal injection of slurry.
  • the slurry injected was composed of peritoneal dialysis solution (DIANEAL® available from Baxter International Inc. of Deerfield, Ill.) and 5% glycerol (w/v).
  • the injection temperature was around ⁇ 1.9° C.
  • the mice were sacrificed 1.5 weeks post injection. At time of sacrifice, both the treated mice and the general cohort were weighed. As depicted in the graph below, the mice receiving treatment with slurry lost, on average, 7.9% of their body weight. In contrast, the normal untreated cohort, gained an average of 21.8% of their body weight.
  • FIGS. 36A-37B slurry injections were utilized to treat sleep apnea in a mouse model.
  • FIGS. 36A and 36B are magnetic resonance (MR) images depicting the cross-sections of a control mouse trachea and adjacent tissue at a baseline and four week follow-up, respectively.
  • FIGS. 37A and 37B are magnetic resonance (MR) images depicting the cross-sections of a treated mouse trachea and adjacent tissue at a baseline and four week follow-up, respectively.
  • the mouse treated in FIGS. 37A and 37B was injected with slurry at a temperature of ⁇ 1.9° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
US15/505,042 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same Abandoned US20170274011A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/505,042 US20170274011A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462042979P 2014-08-28 2014-08-28
US201562121329P 2015-02-26 2015-02-26
US201562121472P 2015-02-26 2015-02-26
PCT/US2015/047301 WO2016033384A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same
US15/505,042 US20170274011A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2015/047301 A-371-Of-International WO2016033384A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same
US17/188,359 Continuation US11938188B2 (en) 2014-08-28 2021-03-01 Injectable slurries and methods of manufacturing and using the same
US17/236,567 Continuation US11826427B2 (en) 2014-08-28 2021-04-21 Compositions and methods for treatment of neurological disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/288,073 Continuation-In-Part US11504322B2 (en) 2014-08-28 2019-02-27 Injectable slurries and methods of manufacturing the same
US17/188,359 Continuation US11938188B2 (en) 2014-08-28 2021-03-01 Injectable slurries and methods of manufacturing and using the same

Publications (1)

Publication Number Publication Date
US20170274011A1 true US20170274011A1 (en) 2017-09-28

Family

ID=55400611

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/505,039 Abandoned US20170274078A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders
US15/505,042 Abandoned US20170274011A1 (en) 2014-08-28 2015-08-27 Injectable slurries and methods of manufacturing and using the same
US17/188,359 Active US11938188B2 (en) 2014-08-28 2021-03-01 Injectable slurries and methods of manufacturing and using the same
US17/236,567 Active 2035-11-04 US11826427B2 (en) 2014-08-28 2021-04-21 Compositions and methods for treatment of neurological disorders
US18/487,887 Active US11964017B2 (en) 2014-08-28 2023-10-16 Compositions and methods for treatment of neurological disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/505,039 Abandoned US20170274078A1 (en) 2014-08-28 2015-08-27 Compositions and methods for treatment of neurological disorders

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/188,359 Active US11938188B2 (en) 2014-08-28 2021-03-01 Injectable slurries and methods of manufacturing and using the same
US17/236,567 Active 2035-11-04 US11826427B2 (en) 2014-08-28 2021-04-21 Compositions and methods for treatment of neurological disorders
US18/487,887 Active US11964017B2 (en) 2014-08-28 2023-10-16 Compositions and methods for treatment of neurological disorders

Country Status (16)

Country Link
US (5) US20170274078A1 (ja)
EP (4) EP3185854B1 (ja)
JP (6) JP6858698B2 (ja)
KR (2) KR102507789B1 (ja)
CN (4) CN106794138B (ja)
AU (4) AU2015308790B2 (ja)
BR (2) BR112017003111B1 (ja)
CA (2) CA2958768C (ja)
DK (2) DK3185876T3 (ja)
ES (1) ES2898097T3 (ja)
MX (3) MX2017002274A (ja)
PL (1) PL3185854T3 (ja)
PT (1) PT3185854T (ja)
SG (4) SG10201913564WA (ja)
WO (2) WO2016033384A1 (ja)
ZA (3) ZA201701048B (ja)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180116868A1 (en) * 2016-11-02 2018-05-03 Christopher J.P. Velis Devices and methods for slurry generation
US9980765B2 (en) 2010-02-15 2018-05-29 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
WO2018128687A1 (en) * 2016-11-18 2018-07-12 Velis Christopher J P Cosmetic appearance of skin
US20190054242A1 (en) * 2017-08-21 2019-02-21 Christopher J.P. Velis Cold slurry syringe
WO2020072983A1 (en) * 2018-10-04 2020-04-09 Miraki Innovation Think Tank Llc Methods of treating subcutaneous fat layers
WO2020077089A1 (en) * 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods for generating slurry
WO2020077090A1 (en) * 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods of generating slurry for injection
WO2021016457A1 (en) 2019-07-24 2021-01-28 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US20210068643A1 (en) * 2017-12-11 2021-03-11 Saban Ventures Pty Limited Suspension cleaning
WO2021062309A1 (en) 2019-09-26 2021-04-01 Miraki Innovation Think Tank, Llc Miniaturized intra-body controllable medical device
WO2021151019A1 (en) 2020-01-23 2021-07-29 The General Hospital Corporation Novel method of enhanced drug delivery to the nervous system
WO2021195582A1 (en) * 2020-03-27 2021-09-30 James Anthony Stefater, Iii Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
US11161156B2 (en) * 2015-10-27 2021-11-02 Hamilton Sundstrand Corporation Powder monitoring
US20210369612A1 (en) * 2018-10-04 2021-12-02 Miraki Innovation Think Tank Llc Slurry and solution compositions
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
WO2022055934A1 (en) * 2020-09-08 2022-03-17 Brixton Biosciences, Inc. Systems and methods for preparing and transporting an injectable slurry
US11439532B2 (en) 2017-04-05 2022-09-13 Miraki Innovation Think Tank Llc Point of delivery cold slurry generation
US11446178B2 (en) 2017-04-05 2022-09-20 Miraki Innovation Think Tank Llc Cold slurry containment
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11490925B1 (en) 2021-06-09 2022-11-08 Mohammed A. Alsufyani Combination ultrasound transducer and fat injecting cannula
US11497544B2 (en) 2016-01-15 2022-11-15 Immunsys, Inc. Immunologic treatment of cancer
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11564830B2 (en) 2016-02-26 2023-01-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
US11576812B2 (en) 2019-04-25 2023-02-14 Carlos Wambier Methods for reducing body fat in a subject
US11696797B2 (en) 2013-12-05 2023-07-11 Immunsys, Inc. Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
US11819451B2 (en) 2020-07-10 2023-11-21 C° Change Surgical Llc Injectable slush feed supply
US11826427B2 (en) 2014-08-28 2023-11-28 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
EP4081746A4 (en) * 2019-12-24 2024-01-17 Miraki Innovation Think Tank LLC SUBSTANTIALLY SOLID SOLUTION, SYSTEMS AND METHODS FOR PRODUCING A SUBSTANTIALLY SOLID SOLUTION AND METHODS FOR ADMINISTRATION THEREOF

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032486A1 (en) 2010-11-16 2022-07-27 TVA Medical, Inc. Devices for forming a fistula
AU2012362524B2 (en) 2011-12-30 2018-12-13 Relievant Medsystems, Inc. Systems and methods for treating back pain
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
CA2887557C (en) 2012-10-11 2022-05-17 Tva Medical, Inc. Devices and methods for fistula formation
IL238516B (en) 2012-11-05 2022-08-01 Relievant Medsystems Inc System and methods for creating curved pathways through bone and regulating the nerves within the bone
ES2743505T3 (es) 2013-03-14 2020-02-19 Tva Medical Inc Dispositivos para la formación de fístulas
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
US10695534B2 (en) 2014-03-14 2020-06-30 Tva Medical, Inc. Fistula formation devices and methods therefor
US10646666B2 (en) 2014-08-27 2020-05-12 Tva Medical, Inc. Cryolipolysis devices and methods therefor
US11534335B2 (en) 2014-10-01 2022-12-27 Cryosa, Inc. Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
US10603040B1 (en) 2015-02-09 2020-03-31 Tva Medical, Inc. Methods for treating hypertension and reducing blood pressure with formation of fistula
EP3402561B1 (en) 2016-01-15 2024-02-28 TVA Medical, Inc. Devices for advancing a wire
US10874422B2 (en) 2016-01-15 2020-12-29 Tva Medical, Inc. Systems and methods for increasing blood flow
WO2017124062A1 (en) 2016-01-15 2017-07-20 Tva Medical, Inc. Devices and methods for forming a fistula
CN109982652B (zh) 2016-09-25 2022-08-05 Tva医疗公司 血管支架装置和方法
AU2018226785A1 (en) * 2017-03-01 2019-10-24 Miraki Innovation Think Tank Llc Cryotherapies
US20210322084A1 (en) * 2018-10-12 2021-10-21 Miraki Innovation Think Tank Llc Cold solution for fat reduction
CN109800472B (zh) * 2018-12-26 2022-09-27 哈尔滨工程大学 一种冰桨接触过程中桨叶表面瞬时冰载压力分布计算方法
AU2020346827A1 (en) 2019-09-12 2022-03-31 Relievant Medsystems, Inc. Systems and methods for tissue modulation
WO2021133720A1 (en) * 2019-12-26 2021-07-01 Miraki Innovative Think Tank Llc Treatment of obstructive sleep apnea
US20230028322A1 (en) * 2019-12-31 2023-01-26 Miraki Innovation Think Tank Llc Cold solution for inducing therapeutic hypothermia
US20230285350A1 (en) * 2020-07-15 2023-09-14 Lyotip, Inc. Formulations for tetracaine and lidocaine
US20220087250A1 (en) * 2020-09-24 2022-03-24 Everest Medical Innovation GmbH Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
JP2024505335A (ja) 2020-12-22 2024-02-06 リリーバント メドシステムズ、インコーポレイテッド 脊椎神経調節の候補の予測
WO2022261494A1 (en) * 2021-06-11 2022-12-15 Brixton Biosciences, Inc. Methods of creating a slurry using liposome emulsions
EP4415725A1 (en) * 2021-10-14 2024-08-21 The General Hospital Corporation Compositions and methods for treatment of obstructive sleep apnea
IL314660A (en) * 2022-02-07 2024-09-01 Martin J Moskovitz Cryosurgical device and materials and methods for its use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200511A1 (en) * 2009-10-30 2014-07-17 Searete Llc Systems, devices, and methods for making or administering frozen particles

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1256372A (en) 1985-04-11 1989-06-27 Koichiro Miyazima Process for producing liposome composition
US5143063A (en) 1988-02-09 1992-09-01 Fellner Donald G Method of removing adipose tissue from the body
JP2512095B2 (ja) * 1988-08-12 1996-07-03 株式会社日立製作所 冷熱発生方法
EP0437479B1 (en) 1988-10-05 1994-06-22 Vestar, Inc. Method of making liposomes with improved stability during drying
US5005364A (en) 1990-02-07 1991-04-09 Nelson William R Apparatus for and method of making and delivering slush ice
IE80926B1 (en) * 1991-07-05 1999-06-30 Nycomed Imaging As Improvements in or relating to contrast agents
US5507790A (en) 1994-03-21 1996-04-16 Weiss; William V. Method of non-invasive reduction of human site-specific subcutaneous fat tissue deposits by accelerated lipolysis metabolism
US5769879A (en) 1995-06-07 1998-06-23 Medical Contouring Corporation Microwave applicator and method of operation
US6126657A (en) 1996-02-23 2000-10-03 Somnus Medical Technologies, Inc. Apparatus for treatment of air way obstructions
US6464697B1 (en) 1998-02-19 2002-10-15 Curon Medical, Inc. Stomach and adjoining tissue regions in the esophagus
US6467953B1 (en) 1999-03-30 2002-10-22 Medical Solutions, Inc. Method and apparatus for monitoring temperature of intravenously delivered fluids and other medical items
US7892229B2 (en) 2003-01-18 2011-02-22 Tsunami Medtech, Llc Medical instruments and techniques for treating pulmonary disorders
US6126684A (en) 1998-04-21 2000-10-03 The Regents Of The University Of California Indwelling heat exchange catheter and method of using same
US6546932B1 (en) 1999-04-05 2003-04-15 Cryocath Technologies Inc. Cryogenic method and apparatus for promoting angiogenesis
JP3111219B1 (ja) * 1999-05-25 2000-11-20 工業技術院長 ポリビニルアルコールを利用した冷熱輸送方法及び装置
HUP0202475A3 (en) 1999-07-16 2004-06-28 Alza Corp A liposome composition having resistance to freeze/thaw damage
US6596333B1 (en) 1999-07-21 2003-07-22 Nestec S.A. Process for producing aerated frozen products
US6413444B1 (en) 1999-08-02 2002-07-02 The University Of Chicago Methods and apparatus for producing phase change ice particulate saline slurries
US7422601B2 (en) * 1999-08-02 2008-09-09 University Of Chicago Office Of Technology Transfer Method for inducing hypothermia
US6244052B1 (en) * 1999-08-02 2001-06-12 The University Of Chicago Method and apparatus for producing phase change ice particulate perfluorocarbon slurries
US6962601B2 (en) 1999-08-02 2005-11-08 University Of Chicago Office Of Technology Transfer Method for inducing hypothermia
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7306591B2 (en) 2000-10-02 2007-12-11 Novasys Medical, Inc. Apparatus and methods for treating female urinary incontinence
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US7897141B2 (en) 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US20030032996A1 (en) * 2001-08-08 2003-02-13 Hallman Arlan Jay Cryogenic massage tube and compress
US6709431B2 (en) 2001-12-18 2004-03-23 Scimed Life Systems, Inc. Cryo-temperature monitoring
ES2342660T3 (es) * 2002-02-26 2010-07-12 Astrazeneca Ab Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
US8840608B2 (en) 2002-03-15 2014-09-23 The General Hospital Corporation Methods and devices for selective disruption of fatty tissue by controlled cooling
CN105030324A (zh) 2002-03-15 2015-11-11 总医院公司 通过受控冷却对脂肪组织进行选择性破坏的方法和装置
US6858025B2 (en) 2002-08-06 2005-02-22 Medically Advanced Designs, Llc Cryo-surgical apparatus and method of use
US7211104B2 (en) 2002-10-08 2007-05-01 Vital Wear, Inc. Contrast therapy system and method
US7083612B2 (en) 2003-01-15 2006-08-01 Cryodynamics, Llc Cryotherapy system
US20040258760A1 (en) 2003-03-20 2004-12-23 Wheatley Margaret A. Isolated nanocapsule populations and surfactant-stabilized microcapsules and nanocapsules for diagnostic imaging and drug delivery and methods for their production
EP1608225A4 (en) 2003-03-26 2007-07-04 Univ Minnesota HEAT METHOD AND COMPOSITIONS
US20060161232A1 (en) 2005-01-18 2006-07-20 Kasza, Oras and Son to The University of Chicago Phase-change particulate ice slurry coolant medical delivery tubing and insertion devices
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
WO2006127897A2 (en) 2005-05-24 2006-11-30 Uab Research Foundation Surgical delivery devices and methods
US7389653B2 (en) 2005-09-15 2008-06-24 The University Of Chicago Medical ice slurry production device
US20070093697A1 (en) 2005-10-21 2007-04-26 Theranova, Llc Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature
US7854754B2 (en) 2006-02-22 2010-12-21 Zeltiq Aesthetics, Inc. Cooling device for removing heat from subcutaneous lipid-rich cells
GB0615287D0 (en) 2006-08-01 2006-09-06 Ares Trading Sa Integral membrane protein
US8192474B2 (en) 2006-09-26 2012-06-05 Zeltiq Aesthetics, Inc. Tissue treatment methods
EP2088950A2 (en) 2006-10-31 2009-08-19 Zeltiq Aesthetics, Inc. Method and apparatus for cooling subcutaneous lipid-rich cells or tissue
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US20080247957A1 (en) 2007-02-16 2008-10-09 Drexel University Advanced drug delivery strategy and platform for minimally-invasive treatment of liver cancer
US20080300571A1 (en) 2007-05-30 2008-12-04 Lepivert Patrick Process and device for selectively treating interstitial tissue
US20090028797A1 (en) 2007-06-14 2009-01-29 Drexel University Novel polymeric ultrasound contrast agent and methods of making thereof
JP5410423B2 (ja) 2007-07-09 2014-02-05 ベロメディックス，インク 低体温装置および方法
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
AU2008309520A1 (en) 2007-10-12 2009-04-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Method for opening tight junctions
WO2009065061A1 (en) 2007-11-14 2009-05-22 Myoscience, Inc. Pain management using cryogenic remodeling
WO2009102367A2 (en) 2007-11-19 2009-08-20 The Regents Of The University Of Colorado Tight junction protein modulators and uses thereof
US20090234325A1 (en) 2008-03-17 2009-09-17 Allan Rozenberg Methods and devices for non-invasive cerebral and systemic cooling
KR20100135863A (ko) 2008-04-01 2010-12-27 더 제너럴 하스피탈 코포레이션 생체조직의 냉각방법 및 냉각장치
US8505315B2 (en) * 2008-04-15 2013-08-13 Uchicago Argonne, Llc Enhanced integrated operation blender based sterile medical ice slurry production device
US7874167B2 (en) 2008-06-06 2011-01-25 C Change Surgical Llc Method and apparatus for producing slush for surgical use
WO2010017556A1 (en) 2008-08-08 2010-02-11 Palomar Medical Technologies, Inc Method and apparatus for fractional deformation and treatment of cutaneous and subcutaneous tissue
US8414356B2 (en) * 2008-10-31 2013-04-09 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US8480664B2 (en) 2009-01-15 2013-07-09 Boston Scientific Scimed, Inc. Controlling depth of cryoablation
US8608696B1 (en) 2009-02-24 2013-12-17 North Carolina State University Rapid fluid cooling devices and methods for cooling fluids
US20110009748A1 (en) 2009-06-11 2011-01-13 Galil Medical Ltd. Transperineal prostate biopsy system and methods
US20130011332A1 (en) 2009-09-15 2013-01-10 Searete Llc, Frozen Compositions and Methods for Piercing a Substrate
US9980765B2 (en) 2010-02-15 2018-05-29 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
CN103118613A (zh) 2010-08-26 2013-05-22 克莱米迪克斯有限责任公司 冷冻消融球囊导管和相关的方法
US9095320B2 (en) 2010-09-27 2015-08-04 CyroMedix, LLC Cryo-induced renal neuromodulation devices and methods
US9439708B2 (en) 2010-10-26 2016-09-13 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
US9060754B2 (en) 2010-10-26 2015-06-23 Medtronic Ardian Luxembourg S.A.R.L. Neuromodulation cryotherapeutic devices and associated systems and methods
EP2651325A4 (en) 2010-12-13 2014-05-07 Myoscience Inc METHOD FOR REDUCING HYPERDYNAMIC FACIAL RIDERS
GB2485864B (en) 2011-07-14 2013-05-29 Ide Technologies Ltd Vacuum ice maker (vim) with an integrated water vapor depostion process
ES2976564T3 (es) 2011-02-01 2024-08-05 Channel Medsystems Inc Aparato para el tratamiento criogénico de una cavidad o luz del cuerpo
CN103747754B (zh) 2011-06-14 2016-07-06 艾琳医药股份有限公司 用于治疗鼻气道的装置
EP2561886A1 (en) 2011-08-23 2013-02-27 Forschungsverbund Berlin e.V. Peptide adjuvant for improved peripheral analgesia
SI2768484T1 (sl) 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizirani liposomi
US9974684B2 (en) 2011-11-16 2018-05-22 The General Hospital Corporation Method and apparatus for cryogenic treatment of skin tissue
CA2860893A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
EP2854681A4 (en) 2012-06-01 2016-02-17 Cibiem Inc PERCUTANEOUS METHODS AND DEVICES FOR CAROTIDE BODY ABLATION
JP6168644B2 (ja) 2012-07-12 2017-07-26 国立大学法人弘前大学 氷スラリー製造装置および氷スラリー製造方法
US9844460B2 (en) 2013-03-14 2017-12-19 Zeltiq Aesthetics, Inc. Treatment systems with fluid mixing systems and fluid-cooled applicators and methods of using the same
US9131975B2 (en) 2013-03-15 2015-09-15 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device
US9023023B2 (en) 2013-03-15 2015-05-05 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device
US9023022B2 (en) 2013-03-15 2015-05-05 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device having release instrument
EP2967706B1 (en) 2013-03-15 2021-09-08 Pacira CryoTech, Inc. Cryogenic blunt dissection devices
US9033966B2 (en) 2013-03-15 2015-05-19 Warsaw Orthopedic, Inc. Nerve and soft tissue ablation device
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
EP3030305B1 (en) 2013-08-05 2020-07-01 Yue Wu System for producing and delivering airless medical ice slurry to induce hypothermia
US9687288B2 (en) 2013-09-30 2017-06-27 Arrinex, Inc. Apparatus and methods for treating rhinitis
US10660688B2 (en) 2014-05-12 2020-05-26 Gary Kalser Cryotherapy device with cryoprotection and methods for performing cryotherapy with cryoprotection
US9763743B2 (en) 2014-07-25 2017-09-19 Arrinex, Inc. Apparatus and method for treating rhinitis
US10646666B2 (en) 2014-08-27 2020-05-12 Tva Medical, Inc. Cryolipolysis devices and methods therefor
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
BR112017003111B1 (pt) 2014-08-28 2021-10-13 The General Hospital Corporation Suspensão de gelo biocompatível e uso da mesma
US9549843B2 (en) 2014-11-30 2017-01-24 C° Change Surgical Llc Production of well-mixed surgical slush
CN204468406U (zh) 2015-02-05 2015-07-15 张淑华 一种新型便携式冷敷装置
US10470813B2 (en) 2015-03-12 2019-11-12 Pacira Cryotech, Inc. Methods and systems for preventing neuroma formations
US20160317346A1 (en) 2015-04-28 2016-11-03 Zeltiq Aesthetics, Inc. Systems and methods for monitoring cooling of skin and tissue to identify freeze events
US10524956B2 (en) 2016-01-07 2020-01-07 Zeltiq Aesthetics, Inc. Temperature-dependent adhesion between applicator and skin during cooling of tissue
CN114576893A (zh) 2016-02-26 2022-06-03 通用医疗公司 医用冰浆生产和递送系统和方法
CN105640642B (zh) 2016-04-07 2018-01-12 上海导向医疗系统有限公司 带扩张球囊的内冷却微波消融针
US11382790B2 (en) 2016-05-10 2022-07-12 Zeltiq Aesthetics, Inc. Skin freezing systems for treating acne and skin conditions
DE102016115387B3 (de) 2016-08-18 2018-02-01 Cardiolectra GmbH Medizinisches Gerät zur Denervierung renaler perivaskulärer Nerven
WO2018044825A1 (en) 2016-08-30 2018-03-08 The General Hospital Corporation Cryotherapy and cryoablation systems and methods for treatment of tissue
BR112019008954A2 (pt) 2016-11-02 2019-07-09 J P Velis Christopher dispositivos e métodos para geração de pasta fluida
KR101905830B1 (ko) 2016-11-15 2018-10-08 울산과학기술원 국부 냉각 마취 장치, 국부 냉각 마취 장치의 제어 방법 및 국부 냉각 마취 장치의 냉각 온도 조절기
US11324673B2 (en) 2016-11-18 2022-05-10 Miraki Innovation Think Tank Llc Cosmetic appearance of skin
EP4427661A2 (en) 2017-02-04 2024-09-11 Vessi Medical Ltd. Cryotherapy device flow control
US9980076B1 (en) 2017-02-21 2018-05-22 At&T Intellectual Property I, L.P. Audio adjustment and profile system
AU2018226785A1 (en) 2017-03-01 2019-10-24 Miraki Innovation Think Tank Llc Cryotherapies
WO2018175111A1 (en) 2017-03-21 2018-09-27 Zeltiq Aesthetics, Inc. Use of saccharides for cryoprotection and related technology
MX2019011996A (es) 2017-04-05 2020-01-20 Miraki Innovation Think Tank Llc Contención de suspensión fría.
JP2020516357A (ja) 2017-04-05 2020-06-11 ミラキ イノベーション シンク タンク エルエルシー 送達点低温スラリ生成
US10500342B2 (en) 2017-08-21 2019-12-10 Miraki Innovation Think Tank Llc Cold slurry syringe
US11523855B2 (en) 2018-09-28 2022-12-13 Team Neuro LLC Spinal pain management system and method
KR20210071009A (ko) 2018-10-04 2021-06-15 미라키 이노베이션 씽크 탱크 엘엘씨 슬러리 및 용액 조성물
TW202025996A (zh) 2018-10-04 2020-07-16 美商米拉齊創新智囊團有限公司 處理皮下脂肪層之方法
MX2021004048A (es) 2018-10-10 2021-08-16 Miraki Innovation Think Tank Llc Sistemas y procedimientos para generar una suspension.
US20210346192A1 (en) 2018-10-10 2021-11-11 Miraki Innovation Think Tank Llc Systems and methods of generating cold slurry for injection
US20210322084A1 (en) 2018-10-12 2021-10-21 Miraki Innovation Think Tank Llc Cold solution for fat reduction
US20220273569A1 (en) 2019-07-24 2022-09-01 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
US12121281B2 (en) 2019-08-07 2024-10-22 Christopher M. Shaari Systems and methods for cryogenic treatment of headache
US20220313484A1 (en) 2019-09-17 2022-10-06 Arrinex, Inc. Apparatus and Methods for Improved Nasal Cavity Treatments
JP2023508941A (ja) 2019-12-24 2023-03-06 ミラキ イノベーション シンク タンク エルエルシー 実質的に固体の溶液、実質的に固体の溶液を生成するシステム及び方法、並びにそれを投与する方法
WO2021133720A1 (en) 2019-12-26 2021-07-01 Miraki Innovative Think Tank Llc Treatment of obstructive sleep apnea
EP4093399A1 (en) 2020-01-23 2022-11-30 The General Hospital Corporation Novel method of enhanced drug delivery to the nervous system
CA3168812A1 (en) 2020-02-19 2021-08-26 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea
CA3173472A1 (en) 2020-03-27 2021-09-30 James Anthony Stefater, Iii Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
US20210330927A1 (en) 2020-04-27 2021-10-28 Black Cat Medical Llc Method of performing cryoneurolysis
US20220071900A1 (en) 2020-09-08 2022-03-10 Brixton Biosciences, Inc. Systems and methods for preparing and transporting an injectable slurry
US20220211923A1 (en) 2020-09-24 2022-07-07 Everest Medical Innovation GmbH Cryoprotective Compositions, Surgical Kits, and Methods for Protection of a Surgical Site During Cryosurgery
US20220087250A1 (en) 2020-09-24 2022-03-24 Everest Medical Innovation GmbH Cryoprotective Compositions and Methods for Protection of a Surgical Site During Cryosurgery
US20220409428A1 (en) 2021-06-23 2022-12-29 Black Cat Medical Llc Method of performing cryoneurolysis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200511A1 (en) * 2009-10-30 2014-07-17 Searete Llc Systems, devices, and methods for making or administering frozen particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Polysorbate-20 2013; http //www.ewg.org 80/skindeep/ingredient/705137/POLYSORBATE-20 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10582960B2 (en) 2010-02-15 2020-03-10 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
US9980765B2 (en) 2010-02-15 2018-05-29 The General Hospital Corporation Methods and devices for selective disruption of visceral fat by controlled cooling
US11696797B2 (en) 2013-12-05 2023-07-11 Immunsys, Inc. Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
US11504322B2 (en) 2014-08-28 2022-11-22 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11471401B2 (en) 2014-08-28 2022-10-18 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US12097282B2 (en) 2014-08-28 2024-09-24 The General Hospital Corporation Injectable slurries and methods of manufacturing the same
US11964017B2 (en) 2014-08-28 2024-04-23 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
US11938188B2 (en) 2014-08-28 2024-03-26 The General Hospital Corporation Injectable slurries and methods of manufacturing and using the same
US11826427B2 (en) 2014-08-28 2023-11-28 The General Hospital Corporation Compositions and methods for treatment of neurological disorders
US11161156B2 (en) * 2015-10-27 2021-11-02 Hamilton Sundstrand Corporation Powder monitoring
US11612426B2 (en) * 2016-01-15 2023-03-28 Immunsys, Inc. Immunologic treatment of cancer
US11497544B2 (en) 2016-01-15 2022-11-15 Immunsys, Inc. Immunologic treatment of cancer
US11564830B2 (en) 2016-02-26 2023-01-31 The General Hospital Corporation Medical ice slurry production and delivery systems and methods
US11890225B2 (en) 2016-11-02 2024-02-06 Miraki Innovation Think Tank Llc Devices and methods for slurry generation
US20180116868A1 (en) * 2016-11-02 2018-05-03 Christopher J.P. Velis Devices and methods for slurry generation
US11000409B2 (en) 2016-11-02 2021-05-11 Miraki Innovation Think Tank Llc Devices and methods for slurry generation
EP4056155A1 (en) 2016-11-02 2022-09-14 Miraki Innovation Think Tank, LLC Devices and methods for slurry generation
WO2018128687A1 (en) * 2016-11-18 2018-07-12 Velis Christopher J P Cosmetic appearance of skin
US11324673B2 (en) * 2016-11-18 2022-05-10 Miraki Innovation Think Tank Llc Cosmetic appearance of skin
US11439532B2 (en) 2017-04-05 2022-09-13 Miraki Innovation Think Tank Llc Point of delivery cold slurry generation
US11446178B2 (en) 2017-04-05 2022-09-20 Miraki Innovation Think Tank Llc Cold slurry containment
US10500342B2 (en) * 2017-08-21 2019-12-10 Miraki Innovation Think Tank Llc Cold slurry syringe
US20190054242A1 (en) * 2017-08-21 2019-02-21 Christopher J.P. Velis Cold slurry syringe
US11241541B2 (en) * 2017-08-21 2022-02-08 Miraki Innovation Think Tank Llc Cold slurry syringe
US20210068643A1 (en) * 2017-12-11 2021-03-11 Saban Ventures Pty Limited Suspension cleaning
CN113164321A (zh) * 2018-10-04 2021-07-23 米拉基创新智库有限责任公司 治疗皮下脂肪层的方法
JP2022508645A (ja) * 2018-10-04 2022-01-19 ミラキ イノベーション シンク タンク エルエルシー 皮下脂肪層を処置する方法
WO2020072983A1 (en) * 2018-10-04 2020-04-09 Miraki Innovation Think Tank Llc Methods of treating subcutaneous fat layers
EP3860548A4 (en) * 2018-10-04 2022-06-01 Miraki Innovation Think Tank, LLC METHODS OF TREATMENT OF SUBCUTANEOUS FAT LAYERS
US20210369612A1 (en) * 2018-10-04 2021-12-02 Miraki Innovation Think Tank Llc Slurry and solution compositions
US20240058267A1 (en) * 2018-10-04 2024-02-22 Miraki Innovation Think Tank Llc Slurry and solution compositions
WO2020077089A1 (en) * 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods for generating slurry
WO2020077090A1 (en) * 2018-10-10 2020-04-16 Miraki Innovation Think Tank Llc Systems and methods of generating slurry for injection
US20210386580A1 (en) * 2018-10-10 2021-12-16 Miraki Innovation Think Tank Llc Systems and methods for generating slurry
US20210346192A1 (en) * 2018-10-10 2021-11-11 Miraki Innovation Think Tank Llc Systems and methods of generating cold slurry for injection
EP3863654A4 (en) * 2018-10-10 2022-07-27 Miraki Innovation Think Tank LLC SYSTEMS AND PROCESSES FOR GENERATION OF SLUDGE
US11576812B2 (en) 2019-04-25 2023-02-14 Carlos Wambier Methods for reducing body fat in a subject
WO2021016457A1 (en) 2019-07-24 2021-01-28 The General Hospital Corporation Methods of creating a substance with different freezing points by encapsulation
WO2021062309A1 (en) 2019-09-26 2021-04-01 Miraki Innovation Think Tank, Llc Miniaturized intra-body controllable medical device
EP4081746A4 (en) * 2019-12-24 2024-01-17 Miraki Innovation Think Tank LLC SUBSTANTIALLY SOLID SOLUTION, SYSTEMS AND METHODS FOR PRODUCING A SUBSTANTIALLY SOLID SOLUTION AND METHODS FOR ADMINISTRATION THEREOF
WO2021151019A1 (en) 2020-01-23 2021-07-29 The General Hospital Corporation Novel method of enhanced drug delivery to the nervous system
CN115884791A (zh) * 2020-03-27 2023-03-31 视酷医疗有限公司 使用医用冰浆来减轻眼表不适的症状的方法
US11653969B2 (en) 2020-03-27 2023-05-23 EyeCool Therapeutics, Inc. Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
WO2021195582A1 (en) * 2020-03-27 2021-09-30 James Anthony Stefater, Iii Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
EP4126055A4 (en) * 2020-03-27 2024-05-01 Eyecool Therapeutics, Inc. METHODS OF ALLEVIATING THE SYMPTOMS OF EYE SURFACE DISCOMFORT USING MEDICAL ICE SUSPENSION
US11399882B2 (en) 2020-03-27 2022-08-02 EyeCool Therapeutics, Inc. Methods of alleviating symptoms of ocular surface discomfort using medical ice slurry
US11819451B2 (en) 2020-07-10 2023-11-21 C° Change Surgical Llc Injectable slush feed supply
WO2022055934A1 (en) * 2020-09-08 2022-03-17 Brixton Biosciences, Inc. Systems and methods for preparing and transporting an injectable slurry
US11241330B1 (en) 2021-04-02 2022-02-08 Brixton Biosciences, Inc. Apparatus for creation of injectable slurry
US11490925B1 (en) 2021-06-09 2022-11-08 Mohammed A. Alsufyani Combination ultrasound transducer and fat injecting cannula

Also Published As

Publication number Publication date
ZA201901279B (en) 2021-08-25
CN106794138A (zh) 2017-05-31
WO2016033380A1 (en) 2016-03-03
US11826427B2 (en) 2023-11-28
DK3185876T3 (da) 2022-10-31
EP3185876A1 (en) 2017-07-05
CN107106481A (zh) 2017-08-29
EP3185876A4 (en) 2018-04-18
PL3185854T3 (pl) 2022-01-31
AU2023214304A1 (en) 2023-08-31
EP3185854A1 (en) 2017-07-05
BR112017003143B1 (pt) 2023-12-05
CN117064838A (zh) 2023-11-17
ZA201701048B (en) 2023-12-20
JP2021152055A (ja) 2021-09-30
EP4176885A1 (en) 2023-05-10
AU2015308794A1 (en) 2017-03-02
JP6858698B2 (ja) 2021-04-21
SG11201701505RA (en) 2017-03-30
US11938188B2 (en) 2024-03-26
CA2958768A1 (en) 2016-03-03
JP7240447B2 (ja) 2023-03-15
JP2017526684A (ja) 2017-09-14
US20210236639A1 (en) 2021-08-05
KR102507789B1 (ko) 2023-03-07
EP3185854A4 (en) 2018-07-25
AU2015308790A1 (en) 2017-03-02
SG10201913564WA (en) 2020-03-30
BR112017003111B1 (pt) 2021-10-13
JP6707525B2 (ja) 2020-06-10
MX2021007621A (es) 2021-08-11
SG10201913572TA (en) 2020-03-30
ZA201701080B (en) 2019-05-29
AU2015308790B2 (en) 2020-12-03
AU2021200481B2 (en) 2023-05-11
AU2021200481A1 (en) 2021-02-25
KR20170044199A (ko) 2017-04-24
US20240042034A1 (en) 2024-02-08
KR20170045330A (ko) 2017-04-26
EP3988105A1 (en) 2022-04-27
CN106794138B (zh) 2021-10-01
EP3185876B1 (en) 2022-08-10
CN113813222A (zh) 2021-12-21
CA2958769A1 (en) 2016-03-03
JP7201727B2 (ja) 2023-01-10
EP3185854B1 (en) 2021-10-06
JP2023060133A (ja) 2023-04-27
MX2017002274A (es) 2017-05-22
ES2898097T3 (es) 2022-03-03
US11964017B2 (en) 2024-04-23
DK3185854T3 (da) 2021-12-20
JP2017529336A (ja) 2017-10-05
JP2020143113A (ja) 2020-09-10
CA2958768C (en) 2023-08-29
WO2016033384A1 (en) 2016-03-03
JP6903792B2 (ja) 2021-07-14
US20210244817A1 (en) 2021-08-12
SG11201701504WA (en) 2017-03-30
US20170274078A1 (en) 2017-09-28
MX2017002271A (es) 2017-05-22
PT3185854T (pt) 2021-12-03
BR112017003111A2 (pt) 2017-12-05
JP2021098748A (ja) 2021-07-01
BR112017003143A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
US11938188B2 (en) Injectable slurries and methods of manufacturing and using the same
US12097282B2 (en) Injectable slurries and methods of manufacturing the same
US11471401B2 (en) Injectable slurries and methods of manufacturing the same
US20210322084A1 (en) Cold solution for fat reduction
TW202025994A (zh) 漿料及溶液組合物
US20230031549A1 (en) Substantially solid solution, systems and methods for generating a substantially solid solution, and methods of administration thereof
KR20210073541A (ko) 피하 지방층을 치료하는 방법
US20240342210A1 (en) Compositions and methods for treatment of obstructive sleep apnea

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION